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CHAPTER I
INTRODUCTION AND
REVIEW OF THE LITERATURE
A.

Objectives
In recent years it has become evident that en-

dogenous compounds are produced from the condensation
of catecholamines (CAs) with aldehydes or a-keto acids
in several pathological conditions.

Of interest in

this dissertation are the simple, 1-alkyl, CA-derived
condensation products, the tetrahydroisoquinolines
(THIQs) which are associated with ethanol
metabolism.

(EtCH)

The close structural similarities be-

tween CA-derived THIQ alkaloids and CA neurotransmitters (NTs) suggests that these alkaloids may be
uniquely qualified to modify biogenic amine function
and metabolism.
Little is specifically known about catecholTHIQ metabolic routes in the nervous system and
to what extent these pathways differ from conventional CA metabolic routes.

It is believed that

a-

methylation and, possibly, conjugation are the major
metabolic routes for THIQs.

However, it is not known

whether the in vivo a-methylation of isoquinolines is
1

2
similar or identical to that of their open-chain precursors, or whether significant stereoselective differences
might exist between isoquinolines and CAs.

These factors

were investigated in this dissertation.
A second possible alternative mode of THIQ metabolism, oxidation to isoquinolines, was surveyed in vivo
as a route to the potential formation of intermediates
which could bind covalently to cellular nucleophiles.
In view of known formation of THIQs and lack of
knowledge about the metabolic consequences of these nowrecognized endogenous CA derivatives, studies of their
effects on the steady state levels of biogenic amines
and acid metabolites in vivo also were pursued.
In order to study THIQ metabolism and to evaluate
the pharmacodynamic events initiated by the presence of
THIQ alkaloids and their possible metabolites, highly
sensitive and specific assays were developed for routine, rapid, analysis of THIQs, biogenic amines and
their respective metabolites in vivo.
In summary, the purpose of the work described in
this dissertation is to elucidate with greater clarity
the discrete metabolic consequences of THIQs in mammalian systems, with the underlying hypothesis that these
condensation products may have neuroregulatory and/or
neuropathological effects.

3

B.

Background

1.

Nonenzymatic Condensations:

Introduction and

Overview
Recent experimental findings demonstrate that
non-enzymatic, bimolecular condensation reactions are
definite occurrences in mammalian homeostatic and disease states.

These reactions, first characterized

in plants, can be generally defined as multistep
processes involving an amine or amino acid and a
carbonyl compound, in equilibrium with the first
product, an imine (Schiff's base), which, if the amine
is derived from a CA, undergo an irreversible intramolecular cyclization to form a second heterocyclic
product, a THIQ molecule (Fig. 1).
Increased levels of catecholamine-carbonyl
condensation products are evident in at least three
pathological conditions in man:

phenylketonuria,

Parkinson's disease, and alcoholism.

The products

have been suggested to be involved in some way in
the sequelae and etiology of these disease states, but
their

involvement is not specifically known.
Parkinson's disease, a progressive neurological

disorder, is characterized by degeneration of the substantia nigra and associated subnormal striatal dopamine (DA) levels.

The clinical characteristics of

4
tr~r,

bradykinesia and rigidity can be relieved to

varying degrees by oral L-3,4-dihydroxyphenylalanine
(L-DOPA) treatment in conjunction with peripheral LDOPA-decarboxylase inhibitors.
et al.

(1)

In 1973, Sandler

unequivocably demonstrated in vivo bio-

synthesis of THIQs in Parkinsonian patients undergoing L-DOPA treatment who were given test doses of
EtOH.

Both salsolinol (SAL.), the DA/acetaldehyde,

(AcA} condensation product, and tetrahydropapaveroline
(THP), the DA/3,4-dihydroxyphenylacetaldehyde (DHPAcA)
condensation product, were found in significant amounts
(Fig. 2).
Further evidence for THIQ synthesis was the finding of
tetrahydroprotoberberines (THPBs) in the urine of
Parkinsonian patients undergoing L-DOPA treatment (2).
THPB alkaloids are suggested to be further "condensation" products derived from in vivo enzymatic conversion of THP via a liver s-adenosyl-methionine-Nmethyl transferase, followed by apparent oxidation
and ring closure (2, 4)

(Fig. 3).

In 1977, Coscia et al.

(3) found yet another

group of THIQs associated with L-DOPA treatment and
Parkinsonism.

The condensation of DA with phenyl-

pyruvates yielded the two 1-benzyl-1-carboxyl-THIQs,
norlaudanosolinecarboxylic acid (NLCA) and 3-0-

5

methylnorlaudanosolinecarboxylic acid (MNLCA)

(Fig. 4).

Interestingly, MNLCA was found to be a normal constituent in control urines as well as in human and rat
brain (3).
Phenylketonuria (PKU) is a well-known disease
resulting from a genetic deficiency in functional
phenylalanine hydroxylase.

As a result, large amounts

of phenylalanine, phenethylamine (PEA) and phenylpyruvate accumulate in the tissues and body fluids of PKU
individuals (5).

Initial studies by Y.H. Loo (6) in

1967 characterized an aldimine condensate of phenethylamine and pyridoxal in the urines of human PKU patients and in the brain and urines of rats made "phenylketonuric" (Fig. 5).
In 1979, Lasala and Coscia, utilizing computerized gas chromatography (GC)/mass spectrometry (MS),
quantitated significant levels of the phenylpyruvate/DA condensation product, 3,4-deoxynorlaudanosolinecarboxylic acid (DNLCA)

(Fig. 6), in the urine of

PKU children and in the urine and brains of rats with
experimentally-induced hyperphenylalaninemia (7).
In 1979, Collins and coworkers reported the
first evidence for the endogenous formation of
THIQs in alcoholic humans with the finding of SAL
and a-methylated SAL (isomer unknown) in the urines
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of patients undergoing detoxification (Fig. 7)
consistent with these findings, Borg et al.

{8, 9).

(10) have

recently found SAL and a-methylated SAL (isomer unknown) in the urine and lumbar spinal fluid of alcoholic patients during and after prolonged intoxication.

Earlier work by Collins and Bigdeli provided

evidence for the formation of SAL in DA-rich brain
regions in acute EtCH-intoxicated rats pretreated
with pyrogallol, a potent catechol-0-methyl transferase (COMT) and aldehyde dehydrogenase inhibitor
(11, 12).

Hamilton et al. provided important addi-

tional evidence for in vivo CNS formation of THIQ
alkaloids with his finding of a-methylated SAL
(isomer unknown) in the corpus striatum of mice
chronically exposed only to EtOH vapors (13), and
no other pharmacological agents.
In summary, non-enzymatic products of CA/carbonyl condensation reactions are apparently present
normally in human metabolism.

However, during vari-

ous pathological conditions their levels appear to
be elevated (14).

The possible physiological and meta-

bolic roles of these compounds are the central questions addressed in this dissertation and will be
discussed in detail.

Of particular interest are the

simple catechol isoquinolines formed during acute

7

and/or chronic alcohol ingestion.
2.

Metabolic Considerations of EtOH Ingestion
EtOH is an unusual psychoactive drug because

of its significant interactions and contributions to
cellular metabolism (15).

The primary metabolic fate

of ingested EtOH is conversion to acetate, which is
then available to enter cellular metabolism at several portals (16).

EtOH is primarily oxidized in the

liver by a cytosolic, nicotinamide-adenine-dinucleotide (NAD+) dependent alcohol dehydrogenase (ADH)
(17- 19)

(Fig. 8).

AcA produced during the oxidation

of EtOH in the liver is metabolized to acetate by mitochondrial NAD+ dependent aldehyde dehydrogenase
(ALDH)

(20- 23).

Although the liver has the enzyma-

tic capacity to metabolize EtCH-derived acetate to
carbon dioxide

(co 2 ),

most of the acetate is released

into the circulation to be metabolized by other organs
(24, 25).

Concomitant with the oxidation of EtOH, cytosolic NAD+ is reduced to NADH by cytosolic ADH.

Most

of the peripheral metabolic changes associated with
chronic EtOH ingestion can be traced back to the substantial decreases in the free NAD+/NADH ratio
(18, 26).

The decrease in the free NAD+/NADH ratio in
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hepatocytes has been shown to have profound effects on
the intermediary metabolism of these cells (19, 27).
This change in redox potential during chronic EtOH
metabolism has been implicated as the cause of decreased lipid oxidation, increased fatty acid synthesis
(28), hyperlactacidemia (29), decreased glucose utilization (30) and diminished activity of the citric acid
cycle (TCA)

(31).

Under these conditions the reoxida-

tion of NADH to NAD+ (the requisite cofactor for cytosolic ADH) in the mitochrondria is rate-limiting with
regard to in vivo oxidation of EtOH (32).
In lieu of these findings, it is interesting
to note that chronic ingestion of EtOH by rats
(27, 33) and humans (34) results in an increased
ability to oxidize EtOH.

Although ADH is the major

enzyme for the oxidation of EtOH in vivo (18, 19), at
least two other enzyme systems, microsomal EtOH oxidizing system (MEOS) and catalase are thought to contribute to the oxidation of EtOH to AcA.

Inducible

changes in the activity of MEOS and catalase have
been proposed to be responsible for the increases in
EtOH oxidation associated with chronic EtOH ingestion (35, 36).
In addition to the metabolic consequences resulting from the oxidation of EtOH to AcA, many of
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the pharmacological effects associated with EtOH ingestion have been ascribed to direct effects of AcA in animal tissues.

Most AcA generated in the liver (as well

as other tissues) is metabolized to acetate by ALDH
(37- 39).

In normal individuals given a moderate

test dose of EtOH, a relatively small portion of AcA
escapes metabolism in the liver and enters circulation
where it is quickly converted to acetate by other organs
(40, 41).

Circulating AcA levels are maintained at a

steady-state level by a balance between the rate of
production and catabolism (42).
Chronic consumption of EtOH has been observed
to alter these "steady-state" levels of AcA in humans
and animals.

It has been suggested that these ob-

served changes are the consequence of adaptive increases in EtOH metabolism with concomitant decreases
in AcA metabolism (35, 43).

Chronic, elevated AcA

levels have been shown to produce structural damage
in mitochondria which in turn leads to a decreased
capacity for the metabolism of AcA (43, 44).
Human alcoholics have been found to have significantly higher circulating AcA levels compared to
controls given a test dose of EtOH (40, 45).

These

observations led to the proposal that a "vicious"
metabolic cycle may develop during chronic alcohol
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abuse (Fig. 9), where, chronic EtOH ingestion leads to
induced EtOH metabolism and concomitant decreases in
AcA metabolism (26, 44).

Subsequently, tissues of the

body are perfused with increasing levels of AcA.

High

AcA levels are believed to contribute not only to the
pathology at the primary site of AcA metabolism (i.e.,
the liver), but also in other peripheral tissues (46)
and possibly the brain.
Little oxidation of EtOH occurs in brain tissue
due to very low ADH activity (1/4000 of liver activity)
(47 - 49).

However, EtCH-derived metabolites and

products (AcA and acetate) produced in the periphery
are metabolized by brain.

AcA is primarily metabolized

to acetate by brain ALDH which has been noted in the
cytosol, mitochondria and microsomes of brain tissue
(50).

Brain ALDHs located in the parenchymal cells

of capillaries, glia and neurons are even suggested
to form a metabolic blood-brain barrier to AcA (51,
52).

Support for this concept comes from data which

reveal multiphasic increases in brain AcA content
corresponding to the saturation of various brain ALDHs
~

by AcA (52, 53) as blood AcA levels increase.
3.

Neuroamine Condensation Products and EtOH:
Pertinent Theories
Recently several hypotheses have attempted to
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relate the potential biosynthesis of CA/aldehyde condensation products or their biotransformed products in
mammalian tissue to some of the actions mediating the
autonomic and behavioral effects of chronic EtOH ingestion.

It has been proposed that these compounds

may also take part in the underlying biochemical mechanisms of EtOH tolerance and dependence (54).
The first hypothesis envisions EtOH, through
its active metabolite, AcA, inducing alterations in
the metabolism of CAs to produce complex aberrant
metabolites (alkaloids) having unique pharmacological
activities (55, 56).

The biogenesis of the proposed

complex alkaloid products would be the result of the
known competitive inhibition of aromatic ALDH (57,
58) by elevated AcA levels (40, 45) generated during
chronic EtOH ingestion.

The inhibition of NAD+

linked ALDH would result in a localized increase
in the highly reactive biogenic aldehydes generated
by monoamine oxidase (MAO) in tissues rich in CAs.
Deprived of their normal metabolic route(_s}, the catechol-aldehydes would be available for condensation
with parent amines (Fig. 10).
This hypothesis is based on the formation of
THP.

THP is the requisite intermediate in the bio-

synthesis of morphine in the opium poppy Papaver
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somniferurn (59).

As early as 1938, Holtz and Heise (60)

speculated that biogenic amines and their aldehyde derivatives may condense in animal tissues.

In 1964,

Holtz et al. provided evidence for the in vitro formation of THP in rat liver homogenates incubated with
DA (61}.

Davis and Walsh, the major proponents of the

complex-THIQ

theor~ utilizing 14 c-DA, provided evidence

for THP formation in rat brainstem homogenates and
showed that formation was enhanced by addition of increasing amounts of AcA to preparations (55, 62).
similar experiments, Davis et al.

(63) incubated

In
14

-c-

norepinephrine (NE) in rat brainstem homogenate and
isolated a substance which apparently had the physical
characteristics of a 4-hydroxylated-THP.

Product for-

mation was enhanced by the addition of barbiturates
to the incubate.

Further evidence to support complex

alkaloid formation, as mentioned in section A., Background, came from the biotransformation of administered
THP to complex THPBs in rat brain and liver
preparations, and the detection of THPBs in the urines
of Parkinson's patients undergoing L-DOPA therapy (64).
Stimulated by these initial findings, numerous
investigators have studied the possible relationships
between the actions of opiates and that of EtOH (65 68).

However, experiments involving THIQ interactions
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with opiate systems (through quantitation of naloxone
displacement and analgesic effects) have yet to provide consistent data which would elucidate an accepted
connection between the molecular mechanisms underlying
EtOH and opiate "addiction."
Independently, but simultaneously, Cohen and
Collins (69 - 71) put forth a second hypothesis delineating the relationship between THIQ formation and
alcohol ingestion.

The major premise of this hypoth-

esis was that AcA, in competition with rapid oxidation and binding to macromolecules, can condense
directly with CAs to form simple 1-alkyl-THIQ alkaloids (Fig. 11).

The similarity in structure be-

tween the THIQs and parent CAs gave rise to the possibility that THIQs could interact with mechanisms
that normally regulate the physiological properties
of CAs.

In this way the THIQs, acting as "false"

NTs, might contribute to the development of EtOH
dependence and/or to the general pharmacological
effects of EtOH ingestion (72).
Although the remainder of this dissertation
will not deal further with the hypothesis concerning
"morphine-like" alkaloids and alcoholism, THP and
other 1-benzyl-THIQs will be included in the discussion on the properties and interactions of THIQs
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with biogenic amine systems.
4.

Tetrahydroisoquinoline Alkaloid Synthesis and
Biosynthesis

a.

Plant Synthesis of THIQs
The THIQ alkaloids are naturally occurring

products in plants; many are known to exhibit pharmacological actions on mammalian nervous and cardiovascular systems (73).

Examples of naturally occur-

ring THIQs are anhalamine and salsoline, which are
found in desert cacti (74), and the saguaro alkaloid
gigantine, which causes hallucinogenic reactions in
squirrel monkeys and cats (75)

(Fig. 12).

In plants,

the formation of THIQ alkaloids is believed to be the
result of the reaction of a-keto acids with an amine
followed by decarboxylation (76).

Morphine biosyn-

thesis in the opium poppy passes through the 1-benzylTHIQ,THP (77).

It is believed that THP is formed

from the condensation of DA with DHPAcA followed by
enzymatic decarboxylation (78) to a 3,4-dihydroisoquinoline (DHIQ) .

The DHIQs and their quaternary

equivalents are established intermediates in the
biosynthesis of plant alkaloids; chirality is developed through asymmetric reduction at this stage
(79)

(Fig. 13).

Morphine and codeine are subse-

quently formed by a series of ring closures and
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methylations followed by partial reduction of the DAderived benzene ring.
SAL and THP formation in mammalian systems by
the THIQ-1-carboxylic pathway is an interesting possibility in light of the finding of several 1-carboxyTHP derivatives in the urine of Parkinsonian and PKU
individuals (3, 7).
b.

General Synthesis and Biosynthesis In Vitro
As early as 1934 researchers showed that DA and

epinine would undergo a spontaneous condensation with
AcA under physiological conditions to form THIQ alkaloids (80).

The formation of THIQs from the condensa-

tion of phenethylamine derivatives and aldehydes (or
a-keto acids) is characterized by the Pictet-Spengler
condensation reaction (81)

(Fig. 1).

Usually, strong

acid and heat have been used to catalyze the reaction
(82).

Pictet-Spengler condensation reactions of CAs

(DA, NE, L-DOPA, and epinephrine; EPI) under physiological conditions with various aldehydes such as
formaldehyde (HCHO)

(70), AcA (83), DHPAcA (62),

and pyridoxal phosphate (84) have been studied.
When a phenolic substituent is located para to the
site of ring closure, the reaction was known to
occur at ambient temperature and neutral pH (69, 80).
This facilitation is negligible under physiological
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conditions if the hydroxyl group is a-methylated or meta
to the site of ring closure (84).
THIQ synthesis has been studied in tissue homogenates (62, 85), isolated intact cells, and organ preparations (70, 86).

Perfusion of cow adrenals with AcA

or HCHO yielded the corresponding THIQs of NE and EPI
(70, 86).

When high concentrations of HCHO were used,

total conversion of EPI and NE to THIQs was observed
(69).

THIQ synthesis has also been observed when per-

fusion with AcA was in the range of that seen in the
blood of human subjects ingesting EtOH (87).
5.

Biogenic Amine Biosynthesis and Metabolism
Before discussing interactions of THIQs with

biogenic amine metabolism, biogenic amine biosynthesis
and metabolism will be considered.

In the mammalian

CNS the CAs, EPI, NE •and DA and the indoleamine, serotonin
a.

(5HT~

are putative neurotransmitters.

Catecholamines
Tyrosine is the only dietary amino acid precus-

sor of DA, NE, and EPI (88).

Phenylalanine through

its conversion in the liver to tyrosine by phenylalanine hydroxylase can also contribute to CA biosynthesis (89).

The rate limiting step in the biosynthesis

of CAs is the conversion of tyrosine to L-DOPA by tyrosine hydroxylase (TH)

(90).

THis a cytoplasmic
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enzyme requiring reduced biopterin (91) as a cofactor,
and is under metabolic feedback inhibition by CA products (92). L-DOPA is rapidly decarboxylated to DA by
L-DOPA decarboxylase (DDC)

(93, 94).

Because of its

low specificity for aromatic amino acids, DDC has
been given the name aromatic acid decarboxylase (AAD) .
It is known to decarboxylate a variety of aromatic
amino acids such as 5-hydroxytryptophan, phenylalanine,
tryptophan and tyrosine.
DA is converted to NE by the enzyme DA-B-hydroxylase (DBH)

(95), an ascorbate -requiring, copper

containing oxygenase (96) •

NE is converted to EPI

by the action of phenylethanolamine-N-methyl-transferase (PMNT) utilizing S-adenosyl-L-methionine
(SAM) as a methyl donor (97).

Evidence is accumu-

lating that EPI is a putative neurotransmitter in
the brainstem (98) .
The only appreciable endogenous metabolites of
DA in vivo are 3,4-dihydroxyphenylacetic acid (DOPAC),
homovanillic acid (4-hydroxy-3-methoxy-phenylacetic
acid, HVA) and 3-0-Methyl-DA(3M-DA)

(100 - 102).

By

use of GC, the endogenous occurrence of 3-methoxy-4hydroxyphenylethylene glycol (MOPEG) and 3,4-dihydroxyphenylethylene glycol (DOPEG) have been demonstrated
as the CNS metabolites of NE in vivo in many species
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(99, 103}.
EPI.

Little is known about central metabolism of

The main metabolites of intraventricularily admin-

istered

3

H-EPI were metanephrine (MET} and vanillylman-

delic acid (3-methoxy-4-hydroxy-mandelic acid, VMA}
(260). CAs are oxidatively deaminated to their correspending catechol-aldehydes by a multiform, mitochrondrial
bound enzyme, MAO.

Investigators have been able to

distinguish two forms of this enzyme by the use of
the selective-irreversible inhibitors clorgyline and
deprenyl (104, 105}.

These studies indicate that

specific substrates for the A species of the enzyme
include SHT, NE and normetanephrine (NORMET} whereas
benzylamine and PEA are the substrates for the B
species and DA is acted on by both.

The aldehydes

are converted by the actions of aromatic aldehyde
dehydrogenases or reductases to corresponding acids
or alcohols.
In addition to oxidative dearnination, a-methylation plays a role in the metabolism of CAs.

COMT

catalyzes the transfer of a methyl group preferentially to the "meta" hydroxyl of substrates containing
the catechol moeity, in the presence of SAM as the
methyl donor and magnesium ions (Mg++} as activator
(106).

To a very limited extent para a-methylation

of endogenous substrates is seen in vivo (107).
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Para 0-methylation of CAs has been shown to be increased
in such pathological conditions as Parkinson's disease
(108), neuroblastoma (109, 110) and pheochromocytoma
(111).

COMT shows low specificity, having as some of

the physiological substrates, EPI, NE, DA, L-DOPA,
DOPEG, and DOPAC (112).

Summaries of possible meta-

bolic routes of NE and DA can be found in Figures 14
and 15, respectively.
b.

Serotonin (5HT)
Tryptophan is the immediate precursor of 5HT

and is converted by the enzyme tryptophan hydroxylase
to 5-hydroxytryptophan {5HTP)

(113).

5HT synthesis

is controlled at the level of tryptophan hydroxylase.
5HTP is converted to 5HT by AAD.

The main metabolic

route for 5HT in the CNS and periphery appears to be
deamination (MAo-A) and subsequent oxidation to 5-hydroxyindoleacetic acid (5HIAA)

(114).

However, fol-

lowing ingestion of large amounts of EtOH, a shift
in peripheral 5HT metabolism is observed.

Increases

in the reductive metabolism of 5HT to 5-hydroxytryptophol (5HTOL) with a concomitant decrease in 5HIAA
are seen in the liver and urine, indicating probable
inhibition of aromatic aldehyde dehydrogenase by
AcA (115)

(Fig. 16).
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c.

General Neurotransmitter Events
In general the biogenic amine NTs are stored in

high concentrations in selective areas of the peripheral
and central nervous systems.

They are actively se-

questered into dense-granular vesicles located in the
presynaptic endings of neurons.

Stimulation of the

nerve releases only those transmitters bound within
the dense-core vesicles.

NTs released into the synap-

tic cleft (interneuronal space) can react with specific post-synaptic receptor sites, initiating a sequence
of molecular events leading to a post-synaptic response.
Inactivation of NTs occurs rapidly, primarily due to
reuptake into the pre-synaptic nerve terminal (>80%).
Neuronal uptake is an unidirectional, sodium-ion (Na+)
dependent, stereospecific, energy requiring mechanism
which follows Michaelis-Menten saturation kinetics.
After reuptake across the neuronal membrane, NTs can
be reincorporated into dense-core vesicles.

Those

NTs not stored become available for catabolism by
MAO and COMT.
6.

Transmitter-Like Properties of THIQs
The similarities between THIQ and CA structure

led to the theory that the THIQs may act as "false"
NTs (69 - 71).

The THIQs would then exert their in-

fluence by interacting with mechanisms that normally
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regulate the physiological properties of CAs.

In sup-

port of this theory, investigators have noted that
THIQs interact with axonal and vesicular transport
systems leading to their uptake and storage in CA
neurons, are released from nerve terminals along with
CAs, and interact with pre- and post-synaptic receptors.
THIQ alkaloids have been shown to block the uptake of CAs by rat synaptosomes and tissue slice preparations.

The addition of THIQs to rat brain synapto-

somes or tissue slices incubated with 3H-CAs resulted
in an efflux of 3H-CAs, probably due to displacement
of the

3

H-CAs from storage vesicles (116 - 118).

6,7-

dihydroxytetrahydroisoquinoline [6,7-(0H) 2 THIQJ has
been shown to be taken up and stored in sympathetic
neurons of rat iris (119, 120).

Similarly, THIQs were

shown to be taken up by rat heart, salivary gland,
iris, and mouse adrenal (121), by capillary endothelial cells, unidentified neuronal components of rat
hypothalamus and hypophysis (122), and by synaptosomal fractions of rat brain (123) •

THIQs have also

been shown to be weak inhibitors of 5-HT uptake into
rat brain slices (124, 125).

Uptake was blocked by

traditional inhibitors of the axonal membrane such
as cocaine and desmethylimipramine (119 - 121).
These results suggest that THIQs and CAs compete with
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each other for transport sites on the neuronal presynaptic membrane (126).
THIQs formed during the perfusion of cow adrenals
with AcA and HCHO were retained in the gland and were
actually found to be stored in the CA-binding vesicles
(127, 128).

6,7-(0H) THIQ was shown to be stored in
2

the CA-binding vesicles of the rat iris and pineal
gland (129).

THP was found to be incorporated into

small granular vesicles when incubated with rat caudate
slices (130).

Vesicular storage of THIQs inCA-binding

vesicles has been shown to be by a reserpine-resistant
mechanism both in vitro (119, 129) and in vivo (120).
Reserpine blocks CA uptake into storage vesicles but
does not affect the axonal uptake mechanisms.

There-

fore, THIQs apparently share axonal transport mechanisms with CAs but binding to storage vesicles occurs
by a mechanism which differs from endogenous amine
binding (131).
THIQs have been shown to be released upon nerve
stimulation via the same mechanisms that control release of endogenous NTs.

EPI and NE condensation

products formed during perfusion of cow adrenals with
AcA were released with endogenous EPI and NE upon
stimulation with acetylcholine or succinylcholine
(132, 133).

In a classical experiment, Mytilineou
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et al. demonstrated the release of 6,7-(0H)

2

THIQ from

NE nerve terminals in rat iris upon electrical stimulation in vivo (120) .

Rats were first depleted of en-

dogenous stores of NE by pretreatment with a-methylpara-tyrosine methyl ester and reserpine.

Subsequently

rats received intravenous injections of 6,7-(0H) 2THIQ
which was shown to accumulate in NE nerve terminals
within the CA-binding vesicles.

Electrical stimula-

tion of the preganglionic fibers of the superior
cervical ganglion showed depletion of the THIQs from
the storage vesicles and caused retraction of the
upper eye lid, protrusion of the eyeball and dilation of the pupil, indicating activation of postsynaptic adrenergic receptors.
The THIQs have been shown to interact with CA
receptors both in vitro and in vivo.

This is not

surprising considering the structural similarities,
for example, between THP and the pharmacological DA
agonists apomorphine and bulbocapnine (Fig. 17)
(134, 135).

As early as 1910, THP had been shown to

have S-agonist actions, lowering blood pressure, increasing heart rate, and causing relaxation of
uterine muscle in cats (136).

Several investigators

have reported potent lipolytic activity for THP
(137 - 140) and to a less extent SAL (138).

The
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S(-) isomer of both compounds exerted the most potent
effects on glycerol and free fatty acid release {138).
THP has been shown to be a moderate DA-dependent adenyl cyclase inhibitor (140 - 142).

SAL also

exerts adenyl cyclase inhibition but to a lesser degree
(141, 142).

The S(-) isomer of both compounds was

again the more effective configuration.

Thus far,

SAL has demonstrated relatively weak S-agonist effects
(137, 143, 144).

However, this THIQ has shown mod-

erate a-antagonism of NE on aorta and vas deferens
of rat (145, 146).

It has also been shown to block

the effects of 5HT stimulation of smooth muscle in
the vas deferens and uterus and block the effect of
oxytocin and vasopressin on the uterus of rat (147).
7.

THIQ/Enzyme Interactions
0-methylation of DA- and NE-derived THIQ alka-

loids has been studied in rat brain and liver homogenates (148) and with purified rat liver COMT (149).
The 0-methylation of THIQs is sensitive to inhibition by pyrogallol, a known COMT inhibitor.

Intra-

cerebroventricular (ICV) administration of THP and
SAL resulted in half life's (T

's) of 24 and 12
112
minutes, respectively (150). These T
's were
112
markedly prolonged by pretreatment with pyrogallol.
In vitro studies have demonstrated that the
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radioactivity derived from

14

c-SAM is incorporated into

the molecular structure of THP and SAL following incubation with rat liver CaMT preparations (151) .

THIQs

are both substrates and competitive inhibitors of caMT
(148, 151 - 153).

SAL and THP have been reported to

be equal or better substrates for in vitro a-methylation by caMT than the endogenous substrates, DA and
NE (149, 151, 153).

Creveling et al. have reported

that both the 6-(meta) and 7-(para) hydroxyls were
a-methylated on two DA derived THIQs by purified rat
liver caMT (154).

Bail et al.

(155) has presented in-

teresting preliminary evidence indicating that SAL and
6,7-(aH) 2 THIQ are largely or exclusively a-methylated on the 7-(para) hydroxyl in rat tissues in vivo.
Extensive a-methylation on the para hydroxyl is simply
not observed with "normal 11 catecholamine and catechol
acid substrates.

Meyerson et al. have demonstrated

that the a-methylation of the complex THIQs, THP and
THPB, is on both the meta and para hydroxyls in vitro
(156), the ratio (of meta/para a-methylation) being
significantly influenced by the optical isomer used.
Locke et al. demonstrated that a-methylated
forms of 3 H-6,7-(aH) DHIQ appeared to be retained in
2
sympathetically innervated tissues such as heart
and salivary glands in amounts greater than or equal
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to the unmetabolized THIQ (121).

As mentioned in sec-

tion I, Collins et al. have found 0-methylated-SAL
(isomer unknown) in the urines of patients undergoing
alcohol detoxification (8) and Hamilton et al.

(13)

have found 0-methylated-SAL (isomer unknown) in the
striata of EtCH-treated mice.

In view of the rapid

formation of a-methylated THIQ alkaloids, it is not
surprising that O'Neill and Rahwan (157) were unable
to detect SAL in the brain of alcohol-treated mice,
in the absence of pretreatment with COMT inhibitors.
With the exception of earlier work by Hjort
et al.

(158, 159) on the gross peripheral pharmacology

of phenolic THIQs, little work has been done on the
physiological and pharmacological properties of 0methylated-THIQs, which are probably the primary metabolites of catechol-THIQ alkaloids in vivo.
To date there is no evidence that the cyclic
THIQ alkaloids are metabolized by MAO.

However, SAL

and THP have been demonstrated to inhibit competitively

the deamination of 5HT in rat brain and liver

homogenates (151, 160).

A variety of THPBs and

THIQs were shown to inhibit both type A and B
species of MAO in rat brain homogenates (161).

It

appears that type A is more sensitive to inhibition
by these substrates.

The THPBs proved to be relatively
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potent and specific inhibitors of MAO type A.

How-

ever, sequential methylation of the hydroxyls on the
berberine ring system resulted in decreased selectivity and potency of MAO inhibition (161).
Compared to classical inhibitors of MAO (i.e.
clorgyline, pargyline, deprenyl, etc.)

(162), the

THIQs appear to be relatively weak to moderate inhibitors of MAO in vitro.

However, the synaptic

properties of uptake and vesicular storage provide
mechanisms for1amplification of THIQ actions. Intraneuronal inhibition of MAO has been investigated both
in vivo and in vitro in the sympathetic nerve plexus
of mouse heart.

Cohen and Katz (163) utilized 6,7-

(0H)2THIQ and demonstrated a 38% increase in

3

H-NE

content with a concomitant decrease in 3H-deaminatedNE in 3 H-NE-treated reserpine-pretreated mice, indieating in vivo inhibition of MAO.

In a complementary

in vitro experiment, Katz and Cohen (164) demonstrated
intraneuronal inhibition of MAO by both SAL and 6,7(OH) THIQ.
2

THP did not elicit potent inhibitory ac-

tions, apparently because of poor uptake into the
nerve plexus.
In vivo experiments in which large doses of
THP and SAL were administered ICV provided evidence
that these THIQ alkaloids were able to alter the
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steady-state levels of endogenous CA and SHT (165).

The

exact mechanism by which their actions are exerted is
still unknown.

Hannigan and Collins (166) demonstrated

that acute peripheral administration of 3-carboxy-salsolinol (3-CSAL), increases SHT levels in the corpus
striatum and hypothalamus of rats, whereas chronic
administration decreased the SHT levels in these tissues.

Livra et al.

(167)

further demonstrated that

THIQ alkaloids can influence cerebral monoamine metabolism in vivo

by the finding that HVA and SHIAA

levels are raised after acute or chronic intraperitoneal (i.p.) injections of THP.

In addition, THP

blocked the L-DOPA-induced increase in HVA as well
as the p-chlorophenylalanine-induced decrease in
SHIAA.

As there is some question as to whether THP

can cross the blood-brain-barrier (BBB), these observed interactions with biogenic amine systems could
depend on a peripheral THP metabolite which enters
the CNS.
The THIQ alkaloids have been shown to be weak
inhibitors of the Na+-Potassium ion (K+) ATPase and
++
Mg ATPase systems. These membrane-bound, active
transport systems participate in modulating the
Na+ and K+ fluxes of excitation and are fundamental
to the energy-dependent reuptake and storage of NTs

29

released at nerve endings (168- 170).
Evidence indicates that SAL is a good in vitro
inhibitor of rat brain TH, the rate limiting step in CA
biosynthesis {171).

Little stereo-specificity was

observed with both the S{-) and R{+) configurations
inhibiting TH activity nearly equally.

The inhibi-

tion was found to be competitive with the pterdine
cofactor {170).

THP proved to be a relatively weak

inhibitor while 4,6,7-trihydroxy-THIQ [4,6,7-{0H)

3

THIQ] and 3-CSAL demonstrated moderate inhibition of
TH activity.

However, in vivo experiments utilizing

SAL, 4,6,7-{0H) THIQ and 3-CSAL did not indicate any
3
in vivo TH inhibition by these compounds {170).
Coscia et al.

{173) have recently reported on

the interactions of a variety of NLCA derivatives with
the enzymes involved in CA metabolism.

The NLCAs in-

hibited TH non-competitively with respect to substrate
and cofactor.

DNLCA was shown to inhibit TH both in

vitro and in vivo.

MNLCA proved to be a potent in

vitro inhibitor of DBH while DNLCA proved less inhibitory and NLCA was not effective.

NLCA was found

to be a competitive inhibitor of NE methylation by
hepatic COMT.

The NLCA derivatives showed only minor

effects on MAO and AAD.
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8.

Possible Oxidative Mechanism For THIQ Metabolism
A growing amount of evidence derived from human

and animal alcohol studies now documents that chronic
EtOH ingestion leads to central and peripheral nerve
damage despite adequate nutrition (174 - 177).

The

precise mechanisms by which ethanol exerts these
chronic toxic effects is still unknown.

Based on sev-

eral lines of evidence, Collins (178) has proposed a
discrete chemical mechanism to explain the cytotoxicity of ethanol, based on the potential involvement
of THIQs.

Considering the chronic nature of THIQ-re-

lated pathological conditions and attendent excess
production of these alkaloids, it is conceivable
that they may have some
effect(s).

uniqu~

pat_hological

Supporting this hypothesis are

experiments by Azevedo and Osswald demonstrating
that administration of a NE-derived THIQ produced
selective ultrastructural degeneration of adrenergic
nerve terminals (179) and hepatotoxicity (180) in
rats.

In addition, Meyers and Melchior (181) dem-

onstrated long-term aberrant behavioral effects (increased ethanol preference) in rats which were induced by ICV administration of THP.
While the major metabolic routes for catecholic THIQs are probably a-methylation and
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conjugation, Collins proposed a minor oxidative metabolic route for THIQ metabolism which would lead to
DHIQs and related N-oxides (Fig. 18).

It was suggested

that the DHIQs, as possible tissue binding agents, may
play a role in the chronic neurotoxic effects of EtOH.
The conversion of THIQs to DHIQs is a well-established pathway in the aldehyde-induced fluorescence
method for histochemical demonstration of biogenic
amines in nerve (182).

The decarboxylation of 1-

carboxyl THIQs to afford DHIQs has been accomplished
by oxidative chemical decarboxylation (183), electrochemical oxidation (184), and by horseradish peroxidase enzyme (78).

In addition, DHIQs derived from 1-

carboxy-THIQs have been demonstrated as reactive intermediates in the biosynthesis of alkaloids in
plants (79, 185).
Because of electronic similarities, the mechanism by which the DHIQs would exert their neurotoxic effects could be analogous to that of 6-hydroxydopamine (60HDA), a potent pharmacological neurotoxin.
The actions of 60HDA are dependent initially on uptake into catecholamine neurons and subsequent oxidation to at least two active species, the quinone and
hydrogen peroxide (186)

(Fig. 19).

Studies of the

interactions of 60HDA with various model proteins
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in vitro (187, 188) and chemical interactions with brain
tissue in vivo (189, 190) clearly demonstrate that 60HDA
covalently reacts with and binds nucleophilic groups on
proteins to form stable covalent bonds (Fig. 20).
At physiological pH, DHIQs are believed to exist
predominately at quinoidamine tautomers (191).

How-

ever, this is based on studies with formaldehyde-related DHIQs; the 1-methyl DHIQs in Fig. 19 have not
actually been studied.

Upon examination, the elec-

tronic and structural similarities between DHIQ quinoidamines and the oxidized electrophilic quinone of
60HDA become strikingly apparent (Fig. 19).

If two

DHIQ tautomers share even a degree of the electrophilic nature of 60HDA, the DHIQs, which are known
to be taken up and stored in CA neurons (192), should
be capable of producing neuronal damage via covalent
attachment to electron-rich cellular ligands (sulfhydryls).
The DHIQs need not have as extensive electrophilic and sulfhydryl-binding capabilities of 60HDA
since they are postulated to form in trace
during chronic ingestion of EtOH.

a~ounts

a-methylation of

THIQs and DHIQs at the meta-hydroxyl (analogous to
that of the open chain catecholamine precussors)
would be expected to block the cytotoxic mechanism.
However, as stated in section 8., evidence now
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indicates that the stereoselective a-methylation patterns of THIQs differs from their catecholamine precussers (155, 156).
9.

Current Analytical Techniques in THIQ Research
It has been recognized that available analyti-

cal methods for the neurochemical

study

of biogenic

amines and their metabolites are often limited, especially when dealing with the endogenous levels
found in small biological samples.

This problem is

exacerbated when dealing with the THIQ alkaloids and
their metabolites since their levels will always be
significantly less than their catecholamine precursors.
Early THIQ research relied heavily on radio-labeled
precursor studies, with separations by thin layer
chromatography (TLC), paper chromatography, paper
electrophoresis and ion-exchange chromatography.
Detection was by combinations of visualizing stains
and radioautography (85, 87, 127, 193 - 195).

These

techniques do not offer a very great degree of selectivity, are not generally sensitive (with the
exception of radio-labeled

studies wnich

a~~

imprac-

tical for fhe.study of endogenous compounds) and are
complicated by lorig ardous·isolation procedures.
More recently, a radioenzymatic method has
been developed for the detection and quantitation
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of SAL (196).

The principle of this technique is based

on enzymatic a-methylation of a catechol by CaMT utilizing

14

c-SAM as cofactor.

Separation is by TLC and

quantitation by liquid scintillation counting of an
extract from the developed plate.

Although this

technique is adequately sensitive for the detection
of endogenous levels of SAL (and probably other THIQs) ,
it is inherently limited by its requirement for catechols.

Therefore, endogenous a-methylated or con-

jugated THIQs cannot

be assayed directly by

this approach.
A significant recent development in the analysis
of biogenic amines and their congeners is HPLC with
electrochemical detection.

This technique offers an

inexpensive but sensitive method for the detection of
picomole concentrations of a range of important phenolic and catecholic compounds (197).

Initial studies

utilizing HPLC with electrochemical detection for the
separation and quantitation of SAL from biological
samples has proven the efficacy of this technique
for THIQ analysis.

HPLC with electrochemical detec-

tion has been utilized for the detection of NE, DA,
5HT, SHIAA, HVA and DaPAC in a variety of combinations in discrete brain regions (197).

What has not

been accomplished is the simultaneous assay of all
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biogenic amines and acids in a given brain structure,
such as DA, DOPAC, HVA, 5HT and 5HIAA.

Separation and

quantitation of these compounds would give a very complete profile of biogenic amine metabolism within the
corpus striatum, for example.
GC/MS is a powerful technique which can conelusively identify neuroamines and derivatives present
in tissue in

femtomole amounts.

Several investiga-

tors have utilized this technique to identify THIQs
in discrete brain regions and biological fluids
(1- 3).

This assay, which appears to be the de-

finitive identification step in neurochemical research, is plagued by two serious drawbacks:

1) com-

plicated and sophisticated instruments requiring expert maintenance and manipulation for both sample
analysis, data

processin~

and interpretation; and,

5
2) a prohibitive cost ($1.5 - 2 X 10 ) •

In lieu of

these problems, the practicality of GC/MS in the
average neurochemical laboratory is limited.
GC with electron capture (EC) detection offers
a second highly sensitive and specific technique for
detection of THIQs with picomole/g tissue sensitivity.

Several investigators have utilized GC with

EC detection, with varying degrees of success, to
determine THIQs in biological samples (8, 11, 13, 155).
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A limiting factor in GC/EC is the ability to separate
compounds with close structural similarities, which
is a function of column efficiency.

To date the

separation of geometrical isomers of biogenic amines
and THIQs on conventional packed GC columns has not
been accomplished.

One possible answer to this

problem is the use of capillary GC columns.

Gen-

erally, capillary columns are those which have internal diameters less than 1 mm.
There are three main types of capillary
columns:

1) micropacked, miniaturized versions of

ordinary packed columns; 2)

support-coated open

tubular (SCOT), which have small particles of solid
support adhered to the wall, but have an unrestricted
flow path; 3) wall-coated open tubular (WCOT) , in
which the liquid phase is directly coated to the
inner wall of the column as a thin film.

With this

type of column, the highest efficiency can be attained (>3,000 theoretical plates/m).
GC/EC utilizing a 25m WCOT capillary chromatograph has been utilized for the separation and
quantitation of the principal_in vitro metabolites
of prostaglandin endoperoxides (198).

Detection

limits equaled or exceeded those obtained for packed
column separations and EC detection.

The

S-antagonist~
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alprenolol and

oxyprenolo~

have been successfully quan-

titated and separated, after isolation from human blood
samples, using EC/GC with a 25M X 0.25mm WCOT glass
capillary column {199).

The lowest detectable amount

of the halogenated {heptafluoracyl) derivatives of
alprenolol and oxprenolol were 2 pg.

Preliminary

studies utilizing model compounds to represent various
classes of biogenic amines indicated that fluoracyl
derivatives of biogenic amines and their metabolites
could be rapidly separated and quantitated by EC/GC
with WCOT columns.
In light of the rapidly accumulating evidence
of THIQ involvement in pathological conditions and the
current state-of-the-art for THIQ and biogenic amine
analysis, highly sensitive and specific assays to
simultaneously detect these compounds and their metabolites are definitely needed.

The requirements

for the assays are the ability to separate a broad
spectrum of closely related compounds at picomole
sensitivity with minimal cost and high reproducibility.
Assays that would meet these requirements would enable
the investigator to assess THIQ involvement in human
pathological conditions.

CHAPTER II
EXPERIMENTAL:
A.

MATERIALS AND METHODS

Standard Analytical Methods for the Characterization of Purity and Identity of Compounds
Synthesized in Section II
Identity and purity of synthesized compounds

were established by

co~parison

of melting

points to literature values, co-chromatography with
authenic samples (when available), infrared (IR)
spectra and nuclear magnetic resonance (NMR) spectra.
HPLC, conventional and capillary GC and TLC techniques
were employed where stated.

HPLC and GC techniques

are discussed in a separate section.
1.

Melting Point
Melting points were obtained (uncorrected) on

dried, crystalline samples utilizing a standard melting
point apparatus (Gallenkamp).
2.

IR Spectrum
IR spectra were performed by making a potassium

bromide (KBR; Mallinckrodt) pellet

with dried crystals.

The spectra between 4000 and 400 nm were obtained on a
grating IR spectrophotometer (Perkin Elmer, model 337).
38
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3.

NMR Spectrum
NMR spectra were performed utilizing deuterium

oxide (D 0) solvent.
2

The spectra between 10 and 0 ppm

(H ) were obtained on a 60 MHz NMR system (Varian 360;
2
courtesy Dr. D. Crumrine, Loyola University, Department of Chemistry) .
4.

TLC
TLC was utilized to assess the progress and com-

pletion of synthetic reactions.
dures were utilized.

Two principal proce-

TLCs of CA-derived THIQs were

performed by spotting 1 - 5 microgram quantities on
4 X 10 em silica gel (Whatman) plates.

The plates

were developed in a butanol/acetic acid (HOAc)/water
(distilled, deionized; dH 2 0)
system.

4/1/1, (V/V/V)

solvent

Starting material, suspected product and a

mixture of the two were run on the same plate simultaneously.

Completed plates were air dried and vis-

ualized in an iodine (I ) chamber unless otherwise
2
described.
Mono- and di-methylated THIQs, DHIQs, and CAs
were separated from their dihydroxylated derivatives
by utilizing
Nagel) .

alumin~~

oxide (AL

o

2 3

) plates (Macherey-

Development was in a chloroform/methanol

(MeOH)/dH 2o, 70/50/5,

(V/V/V) solvent system.

Start-

ing material, suspected product, and a mixture of the
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two were run on the same plate.

Completed plates were

air dried and visualized in an I

2

chamber, or with a

K Fe (CN)
(Mallinckrodt; 0.25 rng/rnl in 0.2
6
3

Na2HP0

4

buffer pH 8-.3} spray which is allowed to dry and then
counter stained with Fe c1

3

(Mallinckrodt; 2.5% Fe c1 3

freshly mixed in 1.5 volumes of acetone)

(70).

B.

Synthesis of Tetrahydroisoquinolines

1.

Synthesis of 1-Methyl-6,7-Dihydroxy-1,2,3,4Tetrahydroisoquinoline (Salsolinol; SAL) HCl
A solution of 1.87 g (8.0 rnMoles) of DA HBr

(Aldrich) in 30 rnl of dH

2

o

was adjusted to pH 4.5

with dilute NH 0H (Mallinckrodt).
4

Ice-cold redis-

tilled AcA (J.T. Baker, 0.79 g; 18 rnMoles) was
added.

The reaction was capped and allowed to stir

slowly at room temperature (RT 0

).

After 3 days, the

reaction was blown to dryness under a stream of extra
dry nitrogen (N Ex)
2

(Benster Welding).

was dissolved in a minimum

vol~.e

The residue

of hot, absolute

EtOH (U.S. Industrial Chern.) and brought to the cloudpoint by drop-wise addition of ethyl acetate (EtOAc).
The suspension was placed in a -20°C freezer overnight, to yield a primary crop of white needle-like
crystals.

The mother liquor was not recrystallized.

The crystals were dried over night in a vacuum dessicator with phosphorous pentoxide (P 2o ) and
5
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characterized by NMR, IR, TLC, GC, HPLC and melting
point comparison (Table 1.)
2.

Synthesis of 1-Methyl-1-Carboxy-6-Hydroxy-7Methoxy-1,2,3,4-Tetrahydroisoquinoline (7-0
MethY-l -1-Carboxy-Salsolinol; 7M-l-CSAL)
A solution of 0.5 g (2.5 mMoles) of 4-0-Methyl-

dopamine
(4.4

(4M-DA)

~~oles)

(HCL salt; Aldrich) and 0.264 g

of pyruvic acid (Sigma) in 10 rnl of

dH o was adjusted with concentrated (cone.) NH 4 0H to
2
pH 4.5 and allowed to stir gently. After 4 days, the
reaction was seeded by scratching the side of the
glass vial with a glass rod and was then placed in a
refrigerator for 1 hr.

The crystals which separated

were filtered and washed with cold dH 2o to remove
any excess pyruvic acid.

The product was dried under

vacuum in the presence of P 2 o and characterized by
5
NMR, IR, TLC, GC, HPLC and melting point comparison
(Table 1).
3.

Synthesis of 1-Methyl-1-Carboxy-6,7-Dihydroxy
1,2,3,4-Tetrahydroisoquinoline (1-CarboxySalsolinol; 1-CSAL)
A solution of 3.0 g (16 mMoles) of DA (HCl

salt; Sigma) and 1.85 g (42 mMoles) pyruvic acid
in 10 ml of dH 2 o was adjusted to pH 4.0 with cone.
NH 4 0H.

After gentle stirring for 4 days at RT 0

'
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reaction was seeded by scratching the side of the reaction vial.

The reaction mixture was placed in a re-

frigerator for 1 hr.

The white powdery crystals which

separated were isolated over a sintered glass filter
and washed with cold dH 2 o to remove excess pyruvic
acid.

The product was dried overnight under vacuum

in the presence of P 2 o and characterized by NMR, IR,
5
GC, HPLC, TLC and melting point comparison (Table 1).
4.

Synthesis of 6,7-Dihydroxy 1,2,3,4-Tetrahydroisoquinoline [6,7-(0H) 2THIQ]HBr
A suspension of DA(HBr salt; 0.233 g; 1 mMole)

in 5 ml of dH
NH 0H.
4

2

o

was adjusted to pH 4.5 with dilute

HCHO (37% solution; Mallinckrodt; 1.23 ml)

was added and the reaction mixture was sealed and
allowed to stir gently at

~0 •

After 24 hr, the re-

action mixture was brought to dryness under a stream
of N Ex
2

The residue was dissolved in a minimum

volume of hot, absolute EtOH and brought to the
cloud-point by dropwise addition of EtOAc.

This

suspension was placed in a -20°C freezer overnight
yielding a primary crop of white needle-like crystals.
The mother liquor was not recrystallized.

The crystals

were dried over night under vacuum in the presence of
P 2o

5

and characterized by NMR, IR, TLC, HPLC, GC, and

melting point comparison (Table 1).
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s.

Conversion of 1-Methyl-6,7-Dimethoxy-3,4-Dihydroisoquinoline (l-ME-6,7DMDHIQ) HCl to 1-Methyl-6,
7-Dihydroxy 3,4 Dihydroisoquinoline (1-ME-6,7DHIQ) HBr
1-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline

HCl (1-Me-6,7-DMDHIQ; synthesized by A. Hashmi, 1978;
1 g; 4.2 m Moles) was placed in a 20 ml screw top vial.
Borontribromide (BBr ; 10 ml; Aldrich) was added, the
3
vial was capped with. a plastic-lined top and the solution
was stirred at

~o

for 3 hr.

The reaction mixture was

blown to dryness in a hood under a stream of N2

Ex

.

The residue was brought up in a minimum volume of hot,
absolute EtOH and brought to the cloud-point by dropwise addition of EtOAc.

The suspension was placed in

a -20°C freezer overnight to yield a crop of yellow
crystals.

The mother liquor was not recrystallized.

The product was dried over night under vacuum in the
presence of P

o

2 5

and characterized by NMR, IR, TLC,

HPLC, GC and melting point comparison (Table 1).
6.

Conversion of 1-Methyl-6-Methoxy-7-Hydroxy3,4-Dihydroisoquinoline

(l-Me~6M-DHIQ)

HCl

to 1-ME-6,7-DHIQ HBr
1-methyl-6-methoxy-7-hydroxy-3,4-dihydroisoquinoline (HCl salt; 0.5 g; 2.2 m Moles; synthesized
by A. Hashmi, 1978) was placed in a 20 ml screw top
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vial.

BBr 3 (10 ml) was added, the vial was capped

with a plastic lined top, and the reaction was
stirred at

~0 •

After 3 hrs, the reaction was taken

to dryness under a stream of N
2

Ex

and the residue

was brought up in a minimum volume of hot, absolute
EtOH.

The solution was brought to the cloud point

by drop-wise addition of EtOAc.

The suspension

was placed in a -20°C freezer overnight to yield
a crop of yellow crystals.

No effort was made to

recrystallize the mother liquor.

The crystals

were dried overnight, under vacuum, in the presence
of P o and characterized by NMR, IR, TLC, GC, HPLC
2 5
and melting point (Table 1).
A summary of selected physical data for the synthesized compounds in section B. can be seen in Table 1.
C.

Techniques for Animal Studies
Compounds utilized in the studies in this disser-

tation were dissolved in sterile, isotonic saline and
administered to male Sprague-Dawley rats (King; 100 +Sg)
either centrally by stereotaxic injections into the lateral cerebral ventricles or peripherally by intraperitoneal injection.

Stereotaxic coordinates (200) were

bregma +0, lateral +1.4 from the midline suture and
verticle +1.4 from the point of entry.

Initial experi-

ments utilizing black I.ndia ink dye confirmed that the
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injections were in the lateral cerebral ventricles.

So-

dium pentobarbital (Abbott) was utilized as the surgical
anesthesia.

It was injected (50 mg/Kg i.p.) 10 minutes

prior to central injections.

At specified time points

after central injections, experimental rats and their
paired saline injected controls were sacrificed by decapitation.

Brain areas and peripheral parts of in-

terest were quickly dissected out according to Holman
et al.
ice.

(201) and placed in plastic weigh boats on dry
The samples were weighed by difference and placed

in plastic centrifuge tubes for extraction.
D.

Extraction of Biogenic Amines, THIQs and Their
Metabolites From Tissue
To each plastic centrifuge tube (7 ml) con-

taining a tissue sample was added 100

~1

of dH

2

o

con-

taining 200 ng of an appropriate internal standard.
The solvent of choice (acid or aqueous EtOH, vide
infra) was added to the plastic centrifuge tube
(5 ml/g) and the sample was homogenized with a 20 sec
burst of a

(Tekmar) Tissue-mizer.

The blades of the

Tissue-mizer were washed with an equal volume of solvent, the washings were combined and the homogenate
then was centrifuged in a Sorvall refrigerated (4°C)
centrifuge at 30,000 X g for 20 min.

The blades of

the Tissue-mizer were scrupulously washed with dH o
2
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and wiped dry between each tissue sample to avoid crosscontamination of samples.
1.

Acid Extraction
Tissue samples were homogenized in either lN HCl

or 0.4N HClo

4

(5 ml/g tissue).

After homogenization

and centrifugation as described (vide supra) , the supernatants were decanted into 20 ml screw-top vials, and
the pHs were adjusted to 5.5 with 2.0N NaOH followed
by 0.2N NaOH.

The neutralized samples were then fro-

zen, lyopholized and stored at -20°C until cation
column isolation and/or direct HPLC analysis.
2.

Ethanol Extraction
Tissue samples were homogenized in aqueous 75%

EtOH (5 ml/g) which had been stored at -20°C.

After

homogenization and centrifugation as described (vide
supra) the supernatants were decanted into 20 ml
screw-top vials and the volumes were doubled with
dH o.
2

These solutions were then frozen, lypholized,

and stored at -20°C until cation column isolation
and/or HPLC analysis.
3.

Strong Cation-Exchange Column Chromatography
Isolation Procedure

a.

Resin Preparation
Dowex AG50-WX, 200/400 mesh (Bio-Rad Labs)
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(H+ form) was stirred with 4 volumes of dH

2

o.

Small par-

ticles were removed from the suspension by allowing the
resin to settle and aspirating any suspended particles
along with the dH

2

o

layer.

This procedure was repeated

until the supernatant was clear, thus indicating a homogenous resin bed.

The aqueous layer was then removed

and replaced with 4 volumes of 2 N NH 40H.

The slurry

was allowed to stir for 1 hr after which it was poured
into a sintered glass filter (coarse-pore) and washed
with dH 2 o until the pH of the effluent was 4.0.

The

resin was resuspended in 4 volumes of 2N HCl and
stirred 1 hr.

It was again washed as described (vide

supra) with dH 2 o until the effluent pH was 4.0.

Ion

exchange columns (2.50 mx 0.6 em) were prepared in
plastic columns equipped with sintered plastic filters (Isolabs).

The columns were washed with 5 ml of

4N HCl/MeOH, 1/1, (V/V) and with dH 20 until pH 4.0.
b.

Column Procedure (Dowex)
The supernatants from acid-precipitated tissues

or solutions of standards (prior to neutralization
and lypholization) were decanted directly onto the
resin and the columns were allowed to drain.

Subse-

quently, the columns were washed with 25 ml of dH 2o,
5 ml of 40/60 dH 2 0/MeOH
4N HCl/MeOH, 1/1 (V/V).

(V/V) and eluted with 5 ml of
The acid/MeOH elution was
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then lyophilized to dryness.

The dried residue was

stored at -20°C for subsequent analysis by HPLC, or
was derivatized and analyzed by GC.
c.

Weak Cation Exchange Column Chromatography
Isolation Procedure

1.

Resin Preparation
BioRex-70, 200/400 mesh, Na+ form (Bio-Rad Labs)

was sized and washed by repetitive stirring and aspiration in 4 volumes of dH o.
2

Once the supernatant was

clear of all fine particulate, the aqueous layer was
removed and replaced with 4 volumes of 3N HCl.

The

resin was stirred for 1 hr, decanted over a sintered
glass funnel (coarse-pore) and washed to pH 5.0 with
dH 2o.

The resin was then resuspended in 5 volumes

of 3N NaOH and allowed to stir for 1 hr, transferred
to a sintered glass funnel (coarse-pore) and washed
to pH 5.0 with dH 2o.

The resin was then suspended

in a O.lM Na HP0 )NaH Po buffer (8.Zg NaH 2 Po 4 ·
2
4
2 4
H2o, 5.68g Na 2HP0 4 ; pH 6.5) containing 10% Na 2EDTA.
2.5 em X 0.6 em resin columns were prepared utilizing
plastic support columns equipped with plastic sintered filters (Isolabs) .

Prior to utilization the

columns were washed with 5 ml of dH o.
2
2.

Column Procedure
The supernatants from neutralized acid-percipitated
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or EtOH-percipitated samples were pipetted onto the
resin and allowed to drain into 20 ml screw top (scintillation) vials.

The columns were then washed with

2 ml of 0.02 M Na HP0 /NaH Po buffer (1.66 g NaH 2
4
2 4
2
po ·H 2o, 1.14 g Na 2 HP0 4 ; pH 6.5) followed by 5 ml of
4
dH o.
2

The primary elution plus buffer and dH 2o

washes contained all acid and amphoteric compounds,
with no detectable amine constituents as ascertained
by HPLC analysis.

The amine compounds were then

eluted with 5 ml of l.ON HCl.

Both fractions were

frozen in a dry-ice/acetone bath and lyophilized
to dryness.

Dried sample residues, after dissolving

in appropriate solvent, were analyzed directly by
HPLC, or were derivatized and analyzed by GC.
E.

Gas Chromatographic Analysis of Catecholamines,
THIQs and Their Metabolites
Quantiation of the isolated catecholamines,

THIQs and respective 0-methylated metabolites were
carried out by EC/GC employing either capillary or
conventional packed columns.
gas chromatograph with
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A Varian model 3700

Ni detector (pulsed mode)

was utilized.
Wall coated, open tubular (WCOT) , glass
capillary columns (10M X 0.25 mm i.d.; Alltech
Assoc.) coated with polyphenylmethylsiloxane (OV-17)

50
were employed.

The splitter at the injection port was

adjusted to a ratio of 10/1.

Head pressure of the
0 F

2

carrier gas, N2 , oxygen free (N 2 2 ) was 0.8 kg/ern •
peak areas and retention times were obtained with a
varian CDS-lllC computing integrator.
Conventional, packed, stainless steel columns
were prepared in our laboratory.

The liquid phase

of choice was a 3% polydirnethylsiloxane (OV-101; applied Sci. Labs.) coated over a Gas Chrorn G, H.P.

100/120 mesh solid support (

ALltec~.Assoc.)

by a sol-

vent evaporation technique, utilizing a rotary flash
evaporator.

Column lengths varied from 1 ft

to 5 ft.

Prepared columns were conditioned at their maximum
operating temperature for 48 hr prior to use.

Peak

areas and retention times were obtained utilizing
a Varian CDS-lllC computing integrator.
1.

Preparation of Fluoracyl Derivatives for GC

a.

Fluoroacyl Derivatives of Non-Carboxylated
Catecholarnines, THIQs and Their 0-Methylated
Metabolites
Initial studies were undertaken with several

types of acylating agents to determine which agent
would give maximum EC responses, completeness of
reactions, derivatives with good stabilities and
optimum separations.

To 1 rng of crystalline compound
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or lyophilized tissue residue in a 20 ml screw-top vial
were added 500

~1

of sequanal grade acetonitrile (ACN;

pierce) and 50

~1

of either heptafluorobutyric anhy-

dride (HFBA), pentafluoropropionylanhydride (PFPA),
or trifluoroacetic anhyhydride {TFAA) (Pierce).

Each

vial was sealed with a plastic lined cap and allowed
to react at

~o

for 30 minutes.

The solutions were

brought to dryness in a hood with a stream of N Ex.
2
The residues were taken up in 1 ml of sequanal grade
toluene

(Pierce).

0.5 ml of 1M (NH 4 ) Po 4 buffer
3

(pH 5.8) was added, the mixture vortexed for 60 sec
and centrifuged in a clinical centrifuge for 5 min.
b.

Formation of Fluoroacyl Derivatives of Carboxylated THIQs and Their a-Methylated Metabolites
To 1 mg of crystalline carboxylated compound

or lyophilized tissue residue in a 20 ml screw-top
vial was added 0.2 ml of hexafluoroisopropanol (HFIP;
Pierce) and 0.05 ml of PFPA.

Each vial was sealed

with a plastic-lined screw-top cap and allowed to
react at

~o

for 20 min.

dry under a stream of N
2

The solutions were blown
Ex

.

The residue was treated

with 0.5 ml of ACN and .05 ml of PFPA for 20 min in
sealed vials.

The samples were again brought to

dryness with N2 Ex I

toluene ( 1 ml) was added, and the

solution was washed with (NH 4 ) 3 Po 4 as described above.
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rmmediately following centrifugation, the toluene phase
(1
F.

~1)

was injected directly into the GC system.
HPLC Methodology
Lyophilized tissue extracts were brought up in

c 18 ,

o.OlN HCl (0.5 ml) and chromatographed on BioSil,
reverse phase; 25 CM columns (Bio-Rad Labs) using
electrochemical detection (B.A.S.; 0.79 volts).

Vari-

ous buffer systems were employed for optimum separations and sensitivity of detection.

The mobile phase

flow rate utilized was generally 1.0 ml/min, as indicated in Results.
1.

Paired-Ion Buffer System
Degassed dH 2 0(-850 ml), 1.1 g (8 mM) heptane-

sulfonic acid (HSA; waters) and 9.7 ml of glacial
HOAc were mixed and adjusted to pH 3.5 with NH 40H,
if necessary.

MeOH (Baker Reagent grade), 100 ml,

was then added and the mobile phase was then brought
to 1 liter with dH o.
2
2.

Ionic-Suppression Buffer System
The ionic-suppression buffer consisted of

0.1 M NaH 2 Po 4 with 1 mM Na

2

EDTA.

The pH was ad-

justed to precisely yield optimum separation (pHs
4.7- 5.2).

3.

Reverse Phase HPLC Column Regeneration
Repeated injections of tissue samples lead
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to loss of separation of isolated compounds even in the
presence of a guard pre-column (Altex).

Reverse phase

columns were cleaned of absorbed tissue components and paired-ion reagent by the technique of
Hannigan (202).

After disconnecting the electrochem-

ical detector, the column was washed successively
with 25 ml of 10 mM oxalic acid (pH 3.5 with concentrated NaOH; Sigma); 25 ml MeOH/dH 20 1/1 (V/V); 25 ml
methylene chloride/tetrahydrofuran, 1/1 (V/V),• 25 ml
MeOH and 25 ml MeOH/dH 2 o, 1/1 (V/V).

of

choice ·t.hen

The mobile phase

.was run through the column for 30

min, the detector reconnected, and allowed to stabilize before use.
G.

Procedure for In Vivo Studies on Stereoselective
0-Methylation of Catechol Isoquinolines
A variety of catechol isoquinolines were inves-

tigated to represent various combinations of catecholamine-carbonyl condensation products.

Compounds

utilized (Fig. 21) were SAL, 1-CSAL, 3-CSAL, 4,6,7(0H)3 THIQ and 1-Me-6,7-DHIQ, a compound which could
theoretically form from the oxidation of SAL or oxidative decarboxylation of 1-CSAL.

A group of rats

were pretreated with the MAO inhibitor

pargyline

(50 mg/Kg, i.p. 2 hr pre-DA}, anesthetized and injected bilaterally in the lateral cerebral ventricles
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with DA.

Separations and quantitations of isoquinolines

and their respective 6- and 7-0-methylated metabolites
were carried out by EC/GC on a WCOT glass capillary column and reverse phase HPLC with electrochemical detection, as described (vide supra) .
Male Sprague-Dawley rats (100 + 5 g) were anesthetized and stereotaxically injected bilaterally (ICV)
with 50

~g

(25

~g/ventricle;

isotonic saline.

12.5

~g/~1;

free base) in

Control rats were given equal volumes

of isotonic saline.

50 min after the ICV injections,

rats were sacrificed by decapitation and the hypothalamus, corpus striatum and hippocampus were removed.
They were weighed, homogenized in 75% aqueous EtOH
with 200 ng of dihydroxybenzylamine (DHBA, internal
standard) and centrifuged as described at 30,000 X g,
4°C for 20 minutes.

The supernatants volumes were

doubled with dH 2 o, were decanted onto Bio Rex-70 cation
exchange columns and differentially eluted for acid
and amine constituents as described.

All fractions

were frozen on dry ice and lyophilized to dryness.
The residues were taken up into O.OlN HCl and analyzed
by HPLC utilizing the ionic suppression buffer system
with electrochemical detection.

An aliquot of each

fraction was taken lyophilized and depending on the
isoquinoline to be assayed differentially derivatized
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for acids (PFPA/HFIP) or amines (HFBA) .
Confirmation of peak identity was determined by
comparison of retention times of authentic standards on
both HPLC and GC as well as co-chromatography with
authentic standards added to derivatized tissue samples.
Regional brain parts of saline-injected controls were
analyzed for the presence of interfering peaks on both
HPLC and GC.
H.

Procedure for Study of the Uptake of Peripheral
Salsolinol Into CNS
Male Sprague-Dawley rats were administered

5 - 20 mg/Kg (i.p.) of SAL (HCl).

At 0.5, 2.0, 5.0,

and 10 hr post-administration, rats were sacrificed
by decapitation.

The hypothalamus, corpus striatum,

and hippocampus were removed, weighed, homogenized
in 0.4N HCL0

4

with 200 ng of DHBA (as internal stand-

ard) and centrifuged at 30,000 X g, 4°C, for 20 minutes.
The pH of the su?ernatant was adjusted to 5.5.

The

supernatan'c the11 was. decanted onto Bio Rex-70 cation
exchange columns and differentially eluted for acid
and amine constituents.

The amine fraction was lyo-

philized, the residue derivatized with HFBA/ACN, and
analyzed by capillary GC with EC detection for the
possible presence of SAL, 7-o-MethyrSAL (7M-SAL) and
6-0-Methyl•SAL ( 6M-SAL) .
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r.

Acute ICV Administration of Catecholic Isoquninolines for Studies on Effects on Endogenous SHT
and Acid Metabolites of Biogenic Amines
Male Sprague-Dawley rats were anesthetized with

Na+ pentabarbital (50 Mg/Kg, i.p.) and stereotaxically
injected ICV bilaterally with 50
free base; 12.5

~g/~1)

~g

(25

~g/ventricle;

of SAL, 4,6,7-(0H) THIQ, 1-CSAL,
3

3-CSAL 1-Me-6,7-DHIQ, orDAin isotonic saline [rats
given DA were pretreated with 50 mg/Kg pargyline (i.p.)
2 hr earlier].

Control animals were given equal vol-

umes of isotonic saline ICV.

50 min after central

administration the animals were sacrificed by decapitation and the hippocampus, hypothalamus, and corpus
striatum were removed, weighed, homogenized in 75%
aqueous ethanol (containing 200 ng of DHBA as internal
standard), and centrifuged at 30,000 X g, 4°C, for
20 min.

The supernatant volumes were diluted with

an equal volume of dH

2

o,

decanted onto Bio Rex-70

cation exchange columns and differentially eluted
for acid and amines constituents.

The acid fractions

were lyophilized to dryness, taken up in 0.5 ml of
0.01 N HCl and analyzed for DOPAC, SHIAA, and HVA in
the corpus striatum and hypothalamus, and for SHIAA
in the hippocampus utilizing paired-ion, reverse
phase HPLC with electrochemical detection.

Amine
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fractions were lyophilized to dryness.
samples were analyzed for SHT as above.

Hippocampal
Hypothalamus

and corpus striatum samples were derivatized with
HFBA/ACN and analyzed for further verification of
stereoselective a-methylation of amine isoquinolines,
possible decarboxylated products of carboxylated
isoquinolines, and DA levels.

However, due to con-

taminated derivatizing reagents from Pierce Chemical
co., these samples were lost.

J.

Procedure for Study of the Half-Life of 7 M-SAL
In the Rat CNS
Male Sprague-Dawley rats were anesthetized with

Na+ pentobarbital and stereotaxically injected ICV as
described with 5 vg/ventricle (5 vg/vl) bilaterally
with 7M-SAL (HCl salt).

Control rats were given equi-

valent volumes of isotonic saline.

1, 3, 6, 12, 24,

and 48 hr after central administration, rats were sacrificed by decapitation and the hippocampus, hypothalamus
and corpus striatum were removed and weighed.

They

were homogenized in 75% aqueous EtOH containing 200 ng
DHBA as internal standard and centrifuged at 30,000 X
g, 4°C for 20 min.
doubled with dH

2

o.

The supernatant volumes were
AJ iquots

of the hypothalamus and

corpus striatum were placed on Bio Rex-70 weak cation
exchange columns and differentially eluted for amine

58

and acid constituents.

The amine fraction was lyophi-

lized to dryness, derivatized with HFBA/ACN, and analyzed
for the presence of 7M-SAL.

The remainder of the

supernatants were lyophilized and the dried residues
were taken up in 0.5 ml of 0.01 N HCl and analyzed by
reverse phase HPLC with electrochemical detection.
Utilizing the ionic suppression buffer, simultaneous
separations and quantitations of DA, DOPAC, 5HT, 5HIAA,
HVA, and 7M-SAL were performed.
K.

Procedure for Study of Peripheral 1-CSAL
Metabolites
Male Sprague-Dawley rats were injected with

1-CSAL (100 mg/Kg, i.p.) daily for 6 days.

On the

7th day, the single dose was increased to 300 mg/Kg
i.p.

Control rats were given equal i.p. volumes of

isotonic saline.

Rats were sacrificed by decapita-

tion 3 hr after the last injection.

Livers, hippo-

campi, hypothalami and corpus striata were removed ,
weighed, homogenized in 0.4N HCl04 containing 200 ng
of DHBA as internal standard, and centrifuged at
30,000 X g, 4°C, for 20 minutes.

The supernatants

were adjusted to pH 5.5 with NaOH and decanted onto
Bio Rex-70 weak cation exchange columns.

The columns

were differentially eluted for acid and amine constituents.

All fractions were frozen on dry ice and
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lyophilized to dryness.

The residue was taken up in

o.Ol N HCl and an aliquot was analyzed by reverse phase
HPLC

with electrochemical detection for the presence

of 1-Me-6,7-DHIQ, SAL and their respective 6- or 7o-methylated metabolites.
tions were utilized.

Two different HPLC condi-

A mobile phase consisting of

0.1 M Na HP0 , 1 mM Na EDTA titrated to pH 7.4 with
2
2
4
0.1 M citric acid, followed by dilution with MeOH
(10% V/V), was employed for DHIQ analysis.

Samples

were analyzed for SAL and its 0-methyl metabolites
with the mobile phase consisting of 0.1 M NaH Po ,
2 4
1 mM Na 2 EDTA pH 5.5, with 5% (V/V) methanol.

pH

adjustments on the mobile phases were made prior to
the addition of methanol to avoid organic solventinduced pertuberations in pH.
The remainder of the O.OlN HCl-suspended sample
was lyophilized to dryness.

HFB-derivatives were pre-

pared and analyzed by capillary GC with EC detection
for the presence of SAL, 1-Me-6,7-DHIQ and their
respective 0-methylated metabolites.
L.

Spectrophotometric Studies of a Series of 1Methyl-6,7-Substituted 3,4-Dihydroisoquinolines
1-Me-6,7-DHIQ, 1-methyl-6-hydroxy-7-methoxy

3,4 dihydroisoquinoline (l-Me-7M-DHIQ}, l-Me-6M-DHIQ,
and 1-Me-6,7-DMDHIQ (HCl salts) were prepared by
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dissolving the appropriate compound (1.0 mg/ml) in dH o
2

u.v.

and storing it at -20°C.

absorption spectra were

obtained on a Perkin-Elmer model 320 spectrophotometer
between 220 and 500

nm~

Excitation and emission spec-

tra were determined at pH 7.0 utilizing and AminicoBowman scanning Spectrophotofluorometer.

The spectra

were examined in O.lN HCl, 0.01 N NaOH, O.lN NaOH and
0.1 M buffers (acetic acid-acetate, pH 3.0 - 5.0; Na+
phosphate, pH 6.0 - 8.0; glycine-NaOH, pH 9.0 - 11.0)
over a pH range of 2 - 13.

All substances studied

exhibited significant fluorescence quenching above
1

~g/ml.

Therefore, the solutions examined were at

concentrations of 1

~g/ml

or less where fluorescence

intensity was proportional to concentration.

Solu-

tions were examined for fluorescence and absorption
immediately after they had been prepared, and fluorescence intensity was always determined at

~o

within

10 - 20 seconds after exposure to exciting light,
to avoid possible photodecomposition and temperature
effects.
M.

Cyclic Voltammetry of DHIQs
Cyclic voltammetry was performed on a direct

current voltammetry instrument (B.A.S.) utilizing
a three electrode linear sweep between +1.2 and -1.2
volts.

The reaction cell was constructed in our
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laboratory from a 20 ml screw top vial.

A teflon-lined,

screw-top cap was modified to accommodate a carbon paste
working electrode, reference electrode (B.A.S.) and
auxillary electrode.

Cyclic voltammograms were re-

corded on an x-y recorder at pH 3.0, 5.0, and 7.4 utilizing a Na+-phosphate-citrate buffer.

The change in

voltage was monitored by use of a voltmeter (Westronics).
All voltammetric studies were done with concentrations
of between 2.0 and 5.0

~g/ml

(free base), scan speed

200 mv/sec at a sensitivity of 2

~A/em.

Scans were

repeated and verified by Dr. Peter Kissinger at the
Bio-Analytical Systems (B.A.S.) Laboratories in West
Layafette, Indiana.
N.

Attempted Synthesis of Glutathione-DHIQ Adducts
Two different DHIQs, 1 Me-6,7-DHIQ HBr (250 mg,

0.95 mMoles) or l-Me-7M-DHIQ HCl (250 mg, 1.17 mMoles)
were each dissolved in 10 ml of dH 2o containing glutathione (GSH; 921 mg, 3.00 rnMoles).
justed to 7.4 with 1.0 M NH 4 0H.

The pH was ad-

The reaction mix-

tures were placed into a warm water bath (37°C) and
gently shaken.

After 10 hr the solutions were frozen

on dry ice and lyophilized to dryness.

5

~g/~1

samples

of the reaction mixture was spotted on an 4 em X 10 em
silica gel plate along with standards of GSH and appropriate DHIQs.

The plates were developed in a butanol/
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HOAc/dH

2

o,

4/1/1 (V/V/V) and visualized by irradiation

under fluorescent light for DHIQs, and ninhydrin (peptide reagent) for GSH.

NMR spectra of the reaction

mixtures were performed in D2o on a varian 360 NMR
spectrophotometer (courtesy of Dr. Dr. D. Crumrin,
Loyola University, Dept. of Chemistry).

HPLC analysis

of the reaction mixture was performed utilizing a .1M
Na HP0 buffer titrated to pH 7.4 with O.lM citric
4
2
acid in 20% (V/V) MeOH.
Combinations of electrochemical/U V or electrochemical/fluorescence detection were utilized to attempt detection of a reaction
product.

o.

Gas Chromatographic Analysis of Ethanol and AcA
EtOH and AcA were analyzed on a Varian 2400

gas chromatograph equipped with a flame ionization
detector.

The column utilized was a 1/8 in X 6 ft

coiled glass column packed in our laboratory with
Porapak QS, 80/100 mesh (Alltech Assoc.).

Empty

glass columns were cleaned by successively drawing
through hot soapy water, acetone, and methanol under
vacuum.

Columns were then dried with N Ex.
2

Deacti-

vation of glass surfaces was accomplished by treatment with Glass-Treet (Alltech Assoc.).

Excess rea-

gent was removed by rinsing with anhydrous MeOH
(25 ml).

Columns were stoppered at one end with a
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glass wool plug and were packed under vacuum by injection of Porapak QS into the open end.

They were vi-

brated during the packing procedure with an engraving
gun.

The columns were then conditioned for 48 hr at

200°C.
P.

Procedure for the Determination of AcA and EtOH
in Human Blood During Alcohol Detoxification
Blood samples (3 - 5) ml were drawn from con-

senting male adults (ages 37 - 54) admitted to the
Alcohol Detoxification Unit at Hines Veterans Administration Hospital.

Non-alcoholic controls were in

the same age range and were psychiatric in-patients
at the hospital.

Both groups were on the same daily

diet and between-meal consumption of foods was restricted.

The blood samples were stored in citrated

tubes in a freezer (-20°C) until preparation for
analysis (6 - 48 hr).

Aliquots (0.2 ml) of blood

were added to 15 ml vacutainers containing 0.5N
HClo 4 (1.0 ml) with 25 rnM thiourea and 50 mg/dl
N-propanol as an internal standard.

Prior to use,

the vacutainers were washed with hot soapy water,
treated with chromerge (S/P), treated further with
hydrogen fluoride (5% solution), rinsed well with
dH 2 o and dried under vacuum at 100°C.

The blood

mixtures (0.2 ml) were immediately mixed and frozen
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over liquid N , blown for -15 sec with N Ex, capped, and
2
2
equilibrated at 37°C for 20 min.

Head space samples

(1 - 2 ml) were taken with a gas-tight syringe (Hamilton)
and analyzed for EtOH, AcA and N-propanol on a PoraPak
QS column (prepared as described in section 0.; Tc
125°C).

=

Standard curves were prepared with AcA, EtOH,

and N-propanol added to normal bloods.

Control bloods

showed negligible formation of AcA during work up procedure.

Standard curves were expressed as concentration

of EtOH or AcA versus the ratio of peak areas of EtOH or
AcA/N-propanol.

CHAPTER III
RESULTS
.. A.

Synthesis of THIQs
Selective physical data for synthesized compounds

is summarized in Table 1.

NMR and IR spectra were con-

sistent with expected structures.

GC and HPLC analysis

determined purity of all synthesized compounds to be
greater than 99%.

TLCs of reaction mixtures verified

that the reactions had gone to completion.
B.

Extraction and Recovery Studies of Biogenic
Amines, THIQs and Their Acid Metabolites
Dihydroxybenzlamine (DHBA) proved to be a good

internal standard, consistently reflecting the recovery
of a variety of compounds.

This verifies the utility

of this compound as an HPLC (203) and GC internal
standard.

Recoveries of all compounds of interest

correlated within 5 - 7% of DHBA recovery.

The ex-

ception was 5HT, whose recovery varied greatly with
the isolation

tech~ique

employed.

Acid extraction utilizing 0.4 N HClo

4

followed

by lyophilization caused almost total loss of isolated
compounds as determined by HPLC analysis.

This loss

could be avoided if the supernatant was adjusted to
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pH 5.5 prior to lyophilization.

When 1.0 N HCl was uti-

lized as the homogenizing medium, no neutralization was
necessary; however, 5HT recovery was only 50% of DHBA
recovery.

When the 1.0 N HCL was adjusted to pH 5.5,

the recovery of DHBA directly reflected 5HT recovery.
overall recovery as determined by HPLC of THIQs, biogenic amines, and their metabolites for the neutralized
acid (1.0 N HCl) extraction technique ranged from 80 85%.

Recoveries were calculated from known standards

added to cerebellar homogenates, which were then carried
through the extraction procedures and compared to identical neat standards by HPLC.
EtOH extraction of tissue samples had the added
advantage of not having to adjust the pH prior to lyophilization or addition to weak cation-exchange columns.
Doubling the volume of the EtCH-extracted supernatant
with dH 2o yielded a solution of pH 5.5.

Utilization of

this technique gave 5HT recoveries by HPLC which were
directly reflected by the recovery of DHBA.

Overall

recoveries of THIQs, biogenic amines and their metabolites after EtOH extraction, lyophilization and direct
HPLC analysis ranged between 85 - 89%.

Recoveries

were calculated, as above, from addition of known
standards to cerebellar homogenates.
The aforementioned extraction techniques
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utilizing HCl, HCl04 , or EtOH, homogenization, pH or
volume adjustment and lyophilization provided reasonable
HPLC chromatograms (see section D).

However, GC anal-

yses utilizing these abbreviated isolation techniques
were unsuccessful.

Attempts to chromatograph the lyo-

philized residues (following derivatization of samples
isolated utilizing any of the three simple extraction
techniques) yielded chromatograms with solvent peaks
exceeding 25 min.

Therefore, a rapid sample "clean-

up" technique using ion-exchange columns was sought.
The use of a strong cation-exchange resin,
Dowex-50, for the separation of amines, acids, and
amphoteric constituents from acid or EtOH extracted
tissue samples had limited success.

The 4N HCl/MeOH

which was necessary for the removal of bound amines
apparently caused significant destruction of the biogenic arnines prior to analysis, as indicated by low
recoveries after (and discoloration during) sample
lyophilization.

In order to increase recoveries,

lower concentrations of acid could be utilized.

How-

ever, this would become impractical due to the large
volume necessary for elution.

Overall recoveries of

THIQs, biogenic amines and their a-methylated metabolites after Dowex, ranged between 25 and 40%, as determined by both HPLC and GC analysis.

These low
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recoveries and the wide range discouraged the use of this
oowex ion-exchange technique.
When the samples were passed through columns containing a weak cation-exchange resin (BioRex-70) which
allowed for selective isolation of amines, acids, and
amphoteric constituents, GC analyses of these fractions
were possible.

The use of BioRex-70 for these isola-

tions was adapted from procedures by Holman (201) and
Barchas (204). Eightyfive%

of·the~carboxylated

THIQs and

and acid metabolites (HVA,5HIAA,DOPAC) of biogenic amines
were detec.ted in the ·primary eluate.

An additional 2 ml

of 0.02 M sodium phosphate buffer eluted an additional
10% of the carboxylated compounds with no detectable
cross contamination from amine constituents.

Non-car-

boxylated THIQs, 5HT, the CAs, and their a-methylated
amine metabolites remained bound to the columns until
elution with 1.0 N HCL.

Overall recoveries of non-

carboxylated THIQs, CAs, and their a-methylated metabolites, directly reflected by the HPLC or GC recovery
of DHBA, were within 83 - 85%.
analysis) was consistently 75%.

5HT recovery (HPLC
A suitable internal

standard was not found for the acid fraction.

The

recoveries for all acid constituents, which were obtained by addition of standards to cerebellar tissue
homogenates and carried through the column procedure,
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were consistently high, ranging from 93 to 95%.

c.

Gas Chromatography of CAs, THIQs, and Their
Metabolites:

Results of Studies on Derivative

Formation and GC Separation Conditions
In general, the HFB-derivatives of non-carboxylated THIQs, CAs, and their respective a-methylated metabolites yielded the higher responses, more symmetrical peaks and better isomer separations, when compared
with the TFA-derivatives.

PFP-derivatives actually

gave EC responses equivalent to HFB-derivatives, but
GC separation of the structural amine isomers (a-methylated metabolites of SAL, 4,6,7,-(aH) 3 THIQ, and
DA} was not achieved following PFPA derivatization.
The a-methylated isomers of carboxylated THIQs were
separable, however, when PFPA was used in combination
with HFIP.
It was found absolutely necessary to wash the derivatives, taken up in toluene, with an aqueous buffer
solution just prior to capillary GC analysis.

The

aqueous washing apparently removed residue fluoroanhydrides and other derivatized volatile compounds
which were contributing significantly to a large
tailing solvent front.
plished with a 1M NH
pH 5.8 - 5.9.

4

This novel step was accomH P0 /(NH ) HPa buffer,
4
2
4 2
4

The aqueous buffer presumably
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hydrolyzed any unreacted fluoroanhydride, and fluoroacids were extracted by the aqueous ammonia.

The

fluoroacyl esters of phenols are reportedly stable
pH~6.0

in H 0 at
2

(205), and the results with THIQs

and CAs indicated this to be true (vide infra) .
The use of aqueous NH 4 + phosphate to wash the
toluene samples is demonstrated in Figure 22.

Recovery

experiments, in which derivatized standards were washed
up to 5 times with the aqueous buffer and injected immediately afterward, showed no significant change in
peak heights, areas, symmetries or retention times.
However, extended storage (72 hrs) of toluene solutions
of derivatized THIQs or CAs in the presence of the
aqueous NH 4 phosphate resulted in a 90 - 100% decrease
in derivative peak heights.
A comparison of capillary versus conventional
column separation of a standard mixture of DHBA, DA,
SAL, 3M-DA, 4M-DA,
Figure 23.

6:r-~-SAL,

and 7M-SAL can be seen in

The conventional 6 foot X 1/4 inch i.d.

packed column was unable to resolve the isomers of
3-M- and 4-M-DA and 6-M and 7-M SAL, despite
various combinations of temperature, pressure, and
liquid phase.
to lose

Packed columns of longer length tended

efficiency, as demonstrated by excessive

peak widths of long retention time compounds, and
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required temperatures which neared or exceeded maximum
operating temperatures of the columns.

Capillary col-

umns were found to separate easily. the 6- and 7..0-Hethyl
isomers of DA, SAL (Fig. 24), 4,6,7,(0H)
l~AL

3

THIQ (Fig. 25),

(Fig. 26), 3-CSAL (Fig. 27) and 1-Me-6,7-DHIQ

(Fig. 28).

A summary of capillary chromatographic con-

ditions, retention times, and minimum detectable quantities is shown in Table 2.
D.

High Performance Liquid Chromatography (HPLC)
of Biogenic Amines, THIQs, and Their Metabolites
The use of paired-ion HPLC permitted simultan-

eous quantitation of either the acid components or
their corresponding amines in a single injection, but
separation of amines and acids in the same mixture
was not achieved in these studies.

Separation of a

standard mixture of DOPAC, SHIAA and HVA by paired
ion chromatography is seen in Figure 29.

Figure 30

shows the separation of NE, DHBA, DA, SAL, and SHT.
Although paired-ion HPLC was able to separate the
6- and 7-C-Methyl. isomers of

I'HIQ~.

the separations

were not adequate enough for precise quantitation.
Small adjustments in paired-ion content, % MeOH and
flow rate were necessary to accommodate the column
degeneration associated with repeated usage.
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The use of the 0.1 M Na

2

Pa -l mM Ha2 EDTA buffer
4

(ionic-suppression buffer) allowed for the simultaneous
separation and quantitation of the biogenic amines and
their acid metabolites.

The pH, now an important pa-

rameter, was manipulated to achieve the best separations.

Because ionic-suppression buffers have pHs of

between 4 and 7, electrochemical oxidation of most biological molecules is easily achieved.

Figure 31 demon-

strates the simultaneous separation of NE, DHBA, DA,
oaPAC, 5HT, 5HIAA, and HVA utilizing the ionic-suppression buffer system.

Utilization of this buffer

18 reverse phase (25 em)
system in combination with a C
column easily separated the following catechol THIQs
and their respective 6-0- and 7-0-methylated isomers:
SAL (Fig. 32), 467-(aH) THIQ (Fig. 33), 1-CSAL (Fig.
3
34), and 3-CSAL (Fig. 35).

With a slight modification,

1-Me-6,7-DHIQ and its two a-methylated derivatives
were also separated (Fig. 36).

A summary of reten-

tion times and selected HPLC parameters is found in
Table 3.
E.

In Vivo Studies of the Stereoselective Brain
a-Methylation of a Variety of catechol Isoquinolines and DA
Electron capture responses for HFB-derivatized

samples of SAL, 467-(aH) THIQ, 1-CSAL, 3-CSAL,
3
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1-Me-6,7 DHIQ, DA and their a-methylated isomers were
all excellent.

Minimum detectable quantities were in

the range of 2 - 10 picomoles~l.

GC recoveries of

all compounds of interest, after EtaH extraction,
Bio Rex-70 isolation, derivatization, and sample cleanup with NH 4 + phosphate buffer, ranged from 80 - 85%.
Representative chromatograms of HPLC and GC separations of SAL/DA (Fig. 37), 4,6,7-(aH)

3

THIQ (Fig.

38), 1-CSAL (Fig. 39), 3-CSAL (Fig. 40), and their
respective a-methyl-metabolites are actual tissueextracted results.

Regional brain chromatograms of

saline-injected controls showed no interfering components at the retention times of any compounds of
interest.
As can be observed in chromatograms, Figures
37 and 39, SAL and 1-CSAL were almost exclusively
0-methylated on the para -7- hydroxyl.

Figures 38

and 40 qualitatively show that 4,6,7-(aH)

3

THIQ and

3-CSAL had mixed stereospecificity to a-methylation
with peaks for both "meta" -6thyl products.

and "para" -1-

a-me-

1-Me-6,7-DHIQ was not a-methylated

to any detectable extent in the 50 minute period following central injection.

DA, injected ICV into

six pargyline-pretreated rats, was apparently a-methylated exclusively in brain on the meta -3-
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hydroxyl (Fig. 37}; if 4M-DA was present, levels were less
than 4 - 5 ng/g striatum.

This result insured that the

7-a-methylation seen with catecholic isoquinolines was
not an artifact of administration.

The quantitative

distribution of brain isoquinoline a-methylation can be
seen in Figure 41.
Tables 4, 5, and 6 show the % stereoselective
a-methylation, % of a-methylation and levels of catechol isoquinoline precursors present in the corpus
striatum, hypothalamus, and hippocampus, respectively.
In the corpus striatum (Table 4} the levels of all catechol isoquinoline presursors were statistically the
same (P>.05}.

However, the% a-methylated [=total

a-methylated products/catechol isoquinoline presursor

(+} total a-methylated products] are significantly
different.

SAL and 4,6,7-(aH} THIQ are statistically
3

a-methylated to the same extent, while 1-CSAL and 3-CSAL
are a-methylated 67% (P<.Ol} and 33% (P<.Ol} of SAL,
respectively.
In the hypothalamus (Table 5) the levels of'the
carboxylated THIQs were 2 to 3 fold as high as SAL and
4,6,7-(aH) 3THIQ.

The% a-methylation for 4,6,7-(aH)

3

THIQ, 1-CSAL, and 3-CSAL are statistically the same
being an average of 70% of the % SAL a-methylation.
In the hippocampus (Table 6) the levels of SAL,
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4,6,~(aH)

3 THIQ and 3-CSAL (1-CSAL was not assayed in

this brain part) were statistically the same as were
the% a-methylation for

4,6,~aH)

3 THIQ and SAL.

How-

ever, the % a-methylation for the carboxylated THIQ
3-CSAL was 36% (P<.Ol) of SAL % a-methylation.
F.

Survey of Salsolinol Uptake into the Rat CNS
After Intraperitoneal Administration
This experiment was undertaken to determine

whether the levels of THIQs found in the CNS after
EtaH administration could have originated in part
from a peripheral source such as liver, heart, or
adrenals, via the cerebral circulation.

GC/EC pro-

vided a means by which the presence of picomole quantities of SAL and a-methylated SALs could be detected
in brain (minimum detectable quantities, 15 - 30
pmoles/g tissue).

The results indicate that at SAL

doses between 5 and 20 mg/kg i.p. SAL and a-methylated SALs were not detectable in the corpus striatum, hypothalamus or hippocampus (data summarized
in Table 7).

The efficacy of GC/EC assay was checked

by the measurements of endogenous DA, which fell
within literature values.

Dopamine levels in the

hypothalamus and corpus striatum were not significantly changed at any SAL dose or at any time point
(not shown).

These results indicate that at doses
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of 20 mg/Kg or less (assumed possible physiological
range), SAL, a representative, simple catechol THIQ,
does not significantly cross the blood/brain barrier.
G.

Effects of Acute ICV Administration of Catechol-Isoquinolines on the Levels of 5HT and
Acid Metabolites in Various Rat Brain Regions
In Tables 9, 10, and 11, the actual values for

5HT, 5HIAA, DOPAC, and HVA in the hypothalamus, hippocampus and corpus striatum in control and isoquinoline (or pargyline/DA) treated animals are tabulated.
In the hippocampus (Table 9, summary Table 8
and Figure 42) where only 5HT and 5HIAA were assayed,
only 1-CSAL failed to significantly increase the
levels of 5HT.

The three THIQs, SAL, 3-CSAL, and

4,6,7-(0H) THIQ, and the DHIQ all increased

the

hippocampal levels of 5HT to 145 - 185% of control
(P<.Ol); 5HIAA levels were altered (increased 27%;
P<.Ol) only by 4,6,7-(0H)

3

THIQ.

Pargyline/DAde-

creased 5HIAA to 26% (P<.Ol) of control as expected.
In the striatum (Table 10, summary Table 8 and
Figure 42), where DOPAC, HVA, and 5HIAA levels were
assayed, 1-CSAL significantly increased both DOPAC
(P<.Ol) and HVA (P<.Ol) 160 and 116% respectively.
3-CSAL significantly lowered 5HIAA levels to 83% of
control (P<.Ol) but did not effect the levels of
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DOPAC or HVA.

Likewise, 4,6,7-(0H) THIQ significantly
3

lowered SHIAA to 82% of control (P<.OS), but had no effect
on the other acid metabolite levels.

sAL did not alter

On the other hand,

the steady-state levels of any of

the acid metabolites in the corpus striatum.
In the hypothalamic tissue (Table 11, summary
Table 8 and Figure 42) DOPAC, HVA, and 5 HIAA were assayed.

A number of significant changes occurred due

to the isoquinolines.

First, levels of the SHT metabo-

lite, SHIAA, were observed to be increased 127% - 178%
(P<.Ol) of control by four of the five isoquinolines,
the exception was SAL.

The levels of the catechol

acid, DOPAC, were lowered to 67% - 79% (P<.Ol) of control values by each of the four THIQs, and additionally,
3-CSAL also decreased HVA levels to 63% of control
(P<.Ol).

Finally, 1-Me-6,7-DHIQ significantly reduced

HVA levels by 26% (P<.Ol).
Thus, it appears that diverse neurochemical
changes occur after large (50

~g)

ICV injections of

catechol isoquinolines, depending on the brain area
examined.

For example, SHIAA levels were changed

(increased) almost exclusively in the hypothalamus
but not in the other two brain areas [slight significant decrease in corpus striatum by 3-CSAL and
4,6,7-(0H) THIQ] by all the isoquinolines except SAL.
3
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Hypothalamic DOPAC levels are decreased by all four
THIQs, but in the striatum, only 1-CSAL affected DOPAC
levels, and this was a 60% increase above control levels.
HVA was only affected by one THIQ in the hypothalamus
(a 37% decrease in its levels by 3-CSAL), and by 1-CSAL
(16% increase) in the striatum.

The DHIQ, l-Me,6,7-

DHIQ had a consistent effect on HVA, decreasing it
20% - 25% in both regions measured.
H.

Half-Life and Effects of 7-Methoxy-Salsolinol
Following Acute ICV Injection
The half life (T 1/2) of ICV administered 7M-SAL

was determined by following its disappearance from selected brain parts.

Analysis by HPLC and GC showed

its T 1/2 to be 133 minutes.
T 1/2

=

This was calculated from

0.693/R; R is equal to the slope of the line

generated from the plot of log 7MSAL
versus time (hr)

(~g/g

tissue)

(Fig. 43).

In tables 12 and 13 the actual values for DA,
SHT, DOPAC, HVA and SHIAA in the hypothalamus, hippocampus and corpus striatum in control and 7M-SAL
treated rats were tabulated.
In the hypothalamus (Table 13A summarized
Figure 44) there is no

observed significant change

in SHT levels over the 48 hr period assayed.

How-

ever, SHIAA levels were increased significantly at
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12 hr (P<.OS), 24 hr and 48 hr (P<.Ol).
in SHIAA were 120%

The increases

137% of control values.

The

initial reciprocal changes (1 hr - 6 hr) seen in the
SHT and SHIAA levels were not significant.
In the hippocampus (Table 13B, summarized in
Figure 44), SHT and SHIAA levels were assayed.

7~1-SAL

significantly increased SHIAA levels 130% - 143% from
6 hr to 48 hr (P<.Ol) while initially (1 hr) lowering
SHIAA 19% (P<.OS).

SHT levels were significantly

affected at 3, 6, 12, and 48 hr after ICV injection.
At 3 hr and 48 hr SHT levels were increased 17% and
29% over control values, respectively (P<.Ol), while
at 6 hr and 12 hr the SHT levels are decreased 17%
and 11% respectively (P<.02)
In the corpus striatum (Table 12, summarized
in Figure 44) DA, DOPAC, HVA, SHT, and SHIAA were
assayed.

Striatal SHIAA was significantly increased

3, 6, and 12 hr (114% - 139%; P<.OS) post ICV injection, while 5HT levels were significantly decreased
only at the 12 hr time point (23%; P<.02).

On the

other hand, Striatal HVA was significantly increased
133% - 192% over central at 1, 3, 12 hr (P<.OS).
levels were decreased 24% at the 48 hr time point
(P<.02) and DOPAC levels were increased 25% at the
3 hr time point (P<.OS).

DA
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Thus, it appears that consistent neurochemical
changes occur after moderate (10

~g)

ICV injections of

7M-SAL in all three brain parts assayed.

For example,

SHIAA was observed to be· increased as was HVA and to
some extent DOPAC in the hypothalamus, hippocampus,
and corpus striatum.

The biogenic amines, SHT and DA,

have scattered changes with the hippocampus having the
most significant SHT alterations.

Examination of the

graphed results (Fig. 44) indicates that the general
trend is an increase in the acid metabolites of the
biogenic amines (DOPAC, HVA, and SHIAA) over time
with no concomitant, consistent changes in DA or SHT
steady-state levels over time.
I.

Results of Chronic Intraperitoneal Administration
of 1-Carboxy-Salsolinol for Determination of In
Vivo Formation of Dihydroisoquinolines froma
Simple 1-Carboxylated THIQ
After chronic 1-CSAL administration, the acid

eluates of Bio Rex-70 isolation columns (amine fraction)
of liver, corpus striatum, hypothalamus and hippocampus were examined for the presence of 1-Me-6,7,-DHIQ,
6- and

7-0-Methy~l-Me-DHIQ,

lated SALs.

SAL and the two a-methy-

There was no chromatographic evidence for

the presence of these compounds which could, in theory,
form from the (oxidative) decarboxylation and/or
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a-methylation of 1-CSAL.

Minimum detectable quantities

for DHIQs were 12 - 24 ng/g.

Excellent recovery (85 -

87%) of the internal standard and biogenic amines insured the integrity of the assay.

Addition of 1-Me-

6,7 DHIQ and its 6- and 7-0-methylated isomers to cerebellar tissue passed through the BioRex-70 column procedure showed that they were exclusively eluted in
the amine fraction.

Qualitative examination of the

primary elution plus 2 ml of .02M Na + phosphate (acid
and amphoteric fraction)

confirmed the presence of

1-CSAL and its 7-0-methylated (carboxylated) metabolite in all regions examined.
were found in this fraction.

No endogenous amines
These results indicate

no substantial formation of DHIQs from 1-carboxy-SAL
in these rat tissues in vivo after chronic i.p. administration of the THIQ.

J.

Spectrophotometric Studies on a Series of
1-Methyl-6,7-Substituted 3,4-Dihydroisoquinolines
The proposed neurotoxicity of dihydroisoquino-

lines is dependent on the structural similarities between the quinoidamine conformation of the DHIQs and
that of the oxidized quinones of 60HDA and of other
related compounds (i.e. 6-amino-dopamine, acetaminophen) .

pH dependency of DHIQs was studied to determine
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the tautomeric form of the DHIQs under physiological
conditions (Fig. 45).
1.

1-Methyl-6,7 Dihydroxy-3,4-Dihydroisoquinoline
(I) and 1-Methyl-6-Hydroxy-7-Methoxy-3,4-Dihydro
Isoquinoline (II)
The UV

absorption spectra of (I) and (II) were

practically identical throughout the entire pH range
tested (Fig. 46).

Between pH 2 and 4 the spectra were

unchanged; however above pH 5.0 they went through
characteristic and similar changes for both substances.
The most prominent change was the appearance of an absorption peak at 384 .nm which reached a maximum of
about pH 9.0.

With a further increase of pH up to

13, the absorption at 384 nrn was considerably diminished.
Compound (I) had very weak fluorescence in the Ph
range of 1 to 5.

However, above pH 5.0 a fluorescence

maximum at 455 appeared which gradually increased with
increasing pH.
380 nrn.

The

The maximum activation peak was at

fluor~:scence

intensity reached a maximum

at approximately pH 8.0; above this pH, the emission
intensity weakened, falling to a small value at higher
pH's (Figures 47 and 48).

Even at pHs 1 to 5, corn-

pound (II) exhibited a fairly strong fluorescence
with a main excitation maximum at 380 nrn and an emission peak at 465 nrn.

Maximum fluorescence intensity
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was attained at about pH 8.0.

The fluorescence decreased

with increasing pH above pH 8.0 (Figures 47 and 48).
2.

1-Methyl-6,7-Dimethoxy-3,4-Dihydroisoquinoline
(III) and 1-Methyl-6-Methoxy-7-Hydroxy-3,4-Dihydroisoquinoline IV
Compounds III and IV had almost identical U V

spectra at all pHs tested (1 to 13).

The spectra

were practically identical between pHs 1 to 7 and
in this range they also resembled the spectra of compounds I and II between pHs 1 and 5 (Fig. 49).

Above

pH 8.0 they underwent reversible and typical changes.
The absorption peak at 350 nm gradually decreased and
disappeared (Fig. 49).
Compound III showed a high fluorescence intensity from pH 1.0 to pH 7.0 with these spectral characteristics:

the main fluorescence excitation peak was

at 350 nm and the main emission maximum was at 450 nm
(Fig. 50).

Above pH 7.5 the fluorescence intensity

decreased, disappearing at higher pH values (Fig. 51).
Compound IV exhibited very weak fluorescence
compared to the other DHIQs tested.

In order to ob-

tain accurate readings the concentrations had to be
increased 10-fold.
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K.

Cyclic Voltarnmetry Studies on a Series of 1-Methyl-6,7-Substituted-3,4-Dihydroisoquinolines
Cyclic vol tarnmograms

were generated from 1-Me-

6,7-DHIQ, l-Me-7M-DHIQ, and l-Me-6M-DHIQ at pHs of
3.0, 5.0, and 7.4.

The results of the cyclic voltam-

metry for these three dihydroisoquinolines can be seen
in Figures 52, 53, and 54, respectively.

The voltam-

mograms are strikingly dissimilar from those generated
from CAs, THIQs and 60HDA-like compounds.
exhibit no reversible reduction peak.

The

The DHIQs
voltammo~

grams generated do exhibit characteristic shifts in
oxidation potentials from higher oxidation potentials
to lower oxidation potentials as the pH is increased
from 3.0 to 7.4.

These shifts indicated an increase

in the ease of oxidation as the pH increased.

The

lack of the reversible reduction peak would indicate
electrochemical oxidation to a compound which is stabilized against reduction.

Further interpretation

of these results are reserved for the discussion section of this dissertation.

A summary of pH versus

oxidation potential is shown in Table 14.
L.

Attempted Synthesis of Glutathione-Dihydroisoquinoline Adducts
TLC analysis of the reaction mixtures of the

dihydroisoquinolines and glutathione indicated that
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no adduct formation had occurred.

Silica Gel TLC plates,

developed with butanol/HOAc/dH 2 0(4/l/l), showed only
one fluorescence spot whose RF (= distance compound
from origin/distance solvent front from origin) was
identical to the respective DHIQ utilized as starting
material.

Staining of the plates with ninhydrin (pri-

mary amine)-reagent to visualize the location of the
glutathione demonstrated one spot whose RF was identical to that of GSH and was substantially different
from that of the respective DHIQs.

No spot appeared

having both fluorescence and ninhydrin staining which
would indicate adduct formation.

The NMR spectra of

the two lyophilized reaction mixtures indicated no
loss of the 5 or 7 position aromatic protons [as seen
in 60HDA-glutathione adduct formation (206)] which
are the expected sites of sulfhydryl addition.

HPLC

analysis of the reaction mixture utilizing combinations of electrochemical/ UV

and electrochemical/

fluorescence detection also indicated no adduct formation.
M.

GC Analysis of Acetaldehyde (AcA) ana Ethanol
(EtOH) in Human Blood
Routine separation of the compounds of in-

terest, AcA, EtOH, and the internal standard N-propanol can be seen in Figure 55.

Standard curves
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prepared with AcA and EtOH were linear for both cornpounds through their physiological ranges,
to 500 rng/dl, AcA, 0.04 to 1.0 rng/dl).
ranged from 60 - 70%.

(EtOH, 2.0

Recoveries

Blood AcA and EtOH levels in

blood samples were not changed by storage at -20°C
for at least 72 hours.
Table 15 shows mean concentrations of EtOH and
AcA in the blood of thirteen male subjects ages 37 54, on admission (day 0) and days 1 - 4.

Blood EtOH

concentrations ranged from 110 to 420 rng/dl in these
subjects, with a mean of 229.7 rng/dl.

The mean EtOH

concentration dropped to 5.0 rng/dl one day after admission and was undetectable on successive days.

Our

subjects' blood AcA concentrations on admission had a
range of 0.06 to 0.70 rng/dl and averaged 0.350 rng/dl.
Blood AcA in our studies were somewhat lower than
those previously reported by Magrinat et al.

(207),

but our subjects' average EtOH concentrations were
also less.

CHAPTER IV
DISCUSSION

-A.

Introduction
These studies have been concerned with several

related aspects of THIQ metabolism.

The metabolic

aspects were studied in vivo to determine in situ
involvement of THIQs with the important CA-rnetabolizing enzymes, COMT and MAO.

First, the cerebral

a-methylation pattern of several 1-alkyl catecholisoquinolines related to the CAs and their effects
on DA, SHT and the acid metabolites of biogenic arnines
were studied.

Since 7M-SAL was the predominant O-rne-

thylated product of SAL in those studies, and since
both of these THIQs form in vivo during alcoholism,
the half-life and effects of 7M-SAL (ICV) ,on endogenous DA, SHT, DOPAC, HVA and 5HIAA levels in various
rat brain regions were determined.

Third, prelirni-

nary investigations on a possible, novel, oxidative
pathway for brain THIQs were initiated.

Analytical

characterization of the possible oxidative products
of this pathway was undertaken.

Simple but highly

sensitive and specific analytical techniques were
developed in order to pursue the above neurochemical
87
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studies.

The technical achievements in this disserta-

tion include improved GC/EC and HPLC/ED methods for
the simultaneous separation and quantitation of biogenic amines, THIQs and their respective metabolites.
Lastly, a procedure for the analysis of EtOH and AcA
in human blood was modified and endogenous AcA levels
were quantitated in alcoholics during detoxification
at Hines V.A. Hospital.
The discussion that follows is organized into
sections headed by a statement of principle which describes the results to be discussed in that section.
B.

Improved Methods

1.

Direct

Ass~y

of Tissue Supernatants by HPLC

with Electrochemical Detection Proves to Be
a Rapid, Facile, and Versatile Way to Measure
Biogenic Amines and Acids in Small Brain Samples
Simultaneous separation and quantitation of DA,
DOPAC, HVA, SHT and SHIAA in small brain parts allows
for direct assessment of the neurochemical consequences
of administered agents.

Comparing control values of

the biogenic amines and acid metabolites obtained by
the HPLC techniques developed in this dissertation
with literature values obtained by a variety of analytical methods, the efficacy of our rapid HPLC assay
system can be seen (Table 16).

All results fall well
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within established literature values.

The ability to

do simple EtOH or HCl extraction and direct analysis
of the supernatant allows for a rapid profile of brain
regions and constitutes a useful and inexpensive addition to the neurochemists' repertoire of analytical
tools.
Reverse phase (RP) is a special case of partition chromatography.

In the case of RP-HPLC, the or-

ganic phase is a permanently bond non-polar stationary
phase.

For our purposes we utilized a 18-carbon alkyl

side chain covalently attached to silica beads.

The

aqueous phase is represented by the buffer system utilized to make the mobile phase.
The separations using this system are achieved
because of the different degrees of interaction of a
compound with both the non-polar stationary phase
and the polar mobile phase.

Compounds with a charged

ionic moiety partition preferentially in the aqueous
phase and move through the column quickly.

Compounds

which are neutral (uncharged) tend to interact with
the hydrophobic phase of the column and to be retained.
The biogenic amines and their acid metabolites
represent a group of ionic compounds whose charge
species are the amine and carboxylic acid, respectively.
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For these ionic species the following equilibrium

.

RCOOH~RCOO

exists;

- +H + ;

~

RNH ~RNH

3

+
2 +H .

By adjusting

the pH of the buffer system in the mobile phase,
the equilibrium can be driven to favor a particular
species.

This technique is called ionic-supression

HPLC chromatography.
Paired ion chromatography (PIC) utilizes a
large organic counter-ion added to the mobile phase
which forms a reversible ion-pair complex with the
ionized sample; this complex behaves as an electronically neutral, non-polar compound.

The use of octane

sulfonic acid (OSA) or heptane sulfonic acid (HSA)
as the paired-ion adds a high degree of hydrophobic
character to the sample through the paired-ion complex.
In order to assure a high paired-ion sample
interaction, the pH of the mobile phase must be
such that the sample is present in its ionic form.
The extent to which the ionized sample and the
counter-ion form an ion-pair complex affects the
degree of retention on the column.
In the separation of biogenic amines by PIC
with alkyl sulfonates, the pH of the mobile phase
should be around 3.5 for best ionic interactions.
Maintaining a pH of around 3.5 ensures that both
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strong and weak bases will be in their ionic forms and
any weak acids will be primarily in the non-ionic
species.
With the use of the electrochemical detection
a second important pH-dependent reaction must be considered.

The oxidations of the phenolic hydroxyls

of the biogenic amines and their metabolites are
also pH dependent.

The lower the pH the higher the

oxidation potential which must be applied.

While

the CAs and catechol isoquinolines and acid metabolites are sufficiently detectable at low pHs (-3.5)
using moderate(+.5-+.8 DC Volts) oxidation potentials,
their a-methylated metabolites have a poor response
at these potentials.

Raising the applied potential

to a value which would allow for detection of a-methylated compounds results in increased oxidation
of buffer components and a general loss in oxidative
specificity.

Increasing the pH of a strong paired-

ion mobile phase to above pH 4.5 results in a low
efficiency of paired-ion-complex formation, thereby
frustrating separations.
For our investigations a HPLC system was developed which utilized a combination of ion-suppression/ion-paired chromatography for the simultaneous separations of DA, DaPAC, 5HT, 5HIAA, HVA,
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a number of THIQs, and their a-methylated metabolites
(208).

The buffer system of 0.1 M Na H2 Pa 4 utilized

1 mM Na 2 EDTA as the weak complexing paired-ion.

EDTA

is an unusual paired-ion because of its four ionizable
carboxylates with PKa's of 2.0, 2.67, 6.16, and 10.26
(209).

The wide range of PKa's allows for this mole-

cule to be utilized as a paired-ion over a broad
spectrum of pHs.
In our studies, the pH which gave maximum
separation and detection within the shortest time
period was determined by titration with concentrated
nitric acid (HNa ) and found to be between 4.7 and 5.2.
3
Between these pHs the ability to detect the whole
spectrum of biogenic amine NT components was excellent.
Separation of these compounds were dependent on pH adjustments as little as 1/10 of a pH unit.

pH adjust-

ments were made to accommodate column deterioration
and THIQs and their a-methylated metabolites which
were present.
Therefore, several significant advantages of
the system developed in this research can be noted:
1) with small change in pH a wide variety of sample
mixtures could be routinely separated and quantitated;
2) the moderate pHs allowed for quantitation of
methylated compounds; 3) the expense of costly

a-
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paired-ion reagents was eliminated; buffer systems can
be made from conventional laboratory reagents.
2.

Capillary GC with EC Detection:

A Very Selec-

tive and Extremely Sensitive Approach to the
Estimation of Biogenic Amines and THIQ Stereoisomers in Discrete Brain Regions
The use of a 10 M, WCOT column in combination
with EC detection yielded the separation of geometrical isomers with sensitivity as low as 3ng/g

tissue.

These results are comparable, in terms of sensitivity,
with those generated by GC/MS.

The use of short

glass capillary columns allowed for unequivocal determination of isolated compounds.

The quantitation

of endogenous brain DA levels and the assessment of
in vivo THIQ metabolism had never been exploited by
glass capillary GC/EC before this work was initiated.
The development, therefore, represents the breaking
of new ground in the field of analytical neurochemistry.

The DA values generated by this technique

compare favorably with established literature values
(Table 16).

Conversion of a conventional EC/GC to

a capillary system is a relatively inexpensive investment (·$380).

However, the result of this modi-

fication is the addition of a highly versatile and
sensitive instrument, without prohibitive cost, to
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the average neurochemistry laboratory.
c.

A Peripherally-Circulating DA-Related THIQ, SAL,
Does Not Enter the Rat CNS
Utilizing the highly sensitive (minimal detec-

table quantity for SAL and a-methylated products, 3 5 ng/g) GC/EC assay developed in this dissertation,
it was found that low peripheral doses (5 - 20 mg/Kg)
of SAL were not taken up into the CNS.

This is not

surprising, considering various CAs, including DA,
the SAL precursor, also do not readily cross the
BBB (217).

The results here are additional support

that SAL (11) and a-methylated-SAL (13), detected in
the CNS of experimental animals after EtaH administration, were derived in situ and were not the result
of peripheral formation followed by uptake.
SAL can be rapidly a-methylated by caMT with
a Km equal to such accepted physiological substrates
as DA and NE (151 - 153).

The greatest activity for

caMT is found in the liver (218) with activity also
found in the spleen, intestines, adrenal gland (219)
and blood (220 - 221) as well as other peripheral
tissues.

Peripherally formed SAL therefore would be

rapidly a-methylated.

Neither of the a-methylated

SAL geometric isomers, Meta-6- or para-7- , were
found in the CNS tissue assayed.
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Peripheral metabolism of SAL could be envisioned
as analogous to that of the THIQ trimetoquinol which
like the sympathomimetic isoproterenol, is metabolized
by a combination of a-methylation and conjugation with
glucuronic acid (222).

Because of these results, our

general approach was to study the interactions of catechol-isoquinolines on the biogenic amine systems
after ICV administration.
D.

Centrally-Administered Isoquinolines Significantly Affect the Levels and Turnover of Regional Brain Arnines and Acid Metabolites to
Differing Degrees, Depending on the Isoquinoline

1.

Hippocampal SHT is Increased with Little Change
in SHIAA Levels
The results of this dissertation indicate that

hippocampal SHT levels are increased significantly when
measured 50 min following ICV administration of a catechol isoquinoline (with the exception of 1-CSAL) ,
but SHIAA levels are unchanged (Fig. 42).

These find-

ings agree with those of Hannigan and Collins (166) and
Patel and Collins (223) that acutely administered THIQs
cause increases in SHT with no increase in SHIAA in
rat brain.
The experiments in this dissertation show
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that a variety of THIQs have this effect indicating
that as a class catechol-isoquinolines can interact
with SHT-systems.

One plausible explanation for in-

creases in SHT without immediate and concomitant
changes in SHIAA would be inhibition of SHT-specific
MAO.

In light of this, these results can be compared

to the in vitro work by Meyerson et al.

(161), who

demonstrated that MAO type A, the SHT specific enzyrne, was more sensitive to inhibition by isoquinolines that MAO type B.
A second possible interpretation of these results
could be blockade of SHT postsynaptic receptors, thereby
increasing steady-state levels of SHT through increased SHT reuptake and storage.

Evidence for THIQ

interactions with SHT receptors was found by Hamilton
et al.

(146) who demonstrated that SAL antagonized

the effects of SHT on smooth muscle.
It is quite possible that catechol-isoquinolines exert their effects at both the level of receptor and as a metabolic inhibitor.

These effects

would be synergistic and could account for increases
in SHT with little or no changes in levels of SHIAA.
What is apparent, is that the catechol-isoquinolines interact with SHT neurons.

It is parti-

cularly relevant and interesting that catechol
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derived isoquinolines can influence SHT-systems.

The

isoquinolines could thus serve as a neuro-modulatory
bridge between CA-systems and SHT systems.

The fact

that isoquinolines have effects on SHT steady-state
levels and are known to inhibit SHT uptake (124)
would reflect their ability to be taken up into SHT
neurons in vivo.

Once taken up, they could act as

"false" SHT-NTs.

The presence of isoquinolines in

SHT-neurons, possible release and receptor interactions and the potential to inhibit SHT deamination,
could lead to aberrant SHT metabolism.
Abnormal SHT metabolism was proposed long ago
by Mcisaac (224) as an etiological factor in some
forms of mental disease.

One feasible hypothetical

situation could occur during chronic EtOH intoxication, where the formation of the THIQ, SAL, within
the CNS has been documented.

THIQ interactions with

SHT-systems would lead to elevated intracellular SHT
levels.

This in turn would lead to increased SHT

and tryptophan condensations with free aldehydes
(AcA) , resulting in the formation of harmaline-like
tetrahydro-S-carboline (THBC)-alkaloids.

THBCs are

themselves potent SHT antagonists and MAO A inhibitors (225) as well as benzodiazepine receptor
blockers (226).

Such harmaline compounds have
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recently been reported in vivo in untreated and alcohol
treated rats (227).

Therefore, the initial formation

of catechol-isoquinolines within CA neurons speculatively could result in a self-perpetuating stimulation of SHT dynamics.

In this way, small quantities

of THIQs generated during chronic EtOH ingestion could
augment their pharmacodynamic effect by generating a
second {possibly more potent) psycho-active agent.
This situation could be described very well by
Thudichum, a pioneer in brain chemistry, who wrote
with foresight in 1884, "many forms of insanity are
unquestionably the external manifestations of the
effects upon brain substance of poisons fermented
within the body" {228).
2.

A 6-Hydroxy-Dihydroisoquinoline Quinoidamine
Significantly Decreases Hypothalamic and Striatal HVA Levels Without Changes in DOPAC
1-Me-6,7-DHIQ lowered HVA levels with no con-

comitant changes in DOPAC in both the corpus striatum and hypothalamus (Fig. 42).

These results may

be due to in vivo inhibition of COMT which was seen
only with 1-Me-6,7-DHIQ.

The unique aspect of this

molecule which may be responsible for this possible
action is its quinoidamine tautomer {vide supra,
section G) which appears to be the predominant
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conformation at physiological pH (Fig. 45).

In the

quinoidamine conformation the catechol moiety no longer
exists; it is an aromatic keto-enol substituent and
closely resembles compounds such as tropolones,
the tropolone-like pyrones, and pyridones, which are
regarded as isosteric with catechol (Fig. 56).

1-Me-

6,7-DHIQ would appear to be isosteric with these inhibitory compounds.

The tropolones, pyrones and pyri-

dones represent a class of short lived, but highly
potent COMT inhibitors.

In vivo, the tropolones ex-

hibit more potency of inhibition than do any catechol
or catechol-derivative inhibitors (229).

It is then

reasonable to assume that the specific affect of 1Me-6,7-DHIQ on the levels of HVA are due to its tropolone-like activity (230).

Further support of this

suggestion is presented in section E of this discussion.
3.

SHIAA Levels Are Increased and DOPAC Levels Are
Decreased in the Hypothalamus by Four of the
Five Catechol Isoquinolines Examined
The decreased hypothalamic DOPAC with increased

5HIAA, which was potentiated by all the isoquinolines
tested with the exception of SAL, reflects differing
effects of catechol isoquinolines within SHT- and DAneurons (Fig. 42).

The increase in SHIAA could be
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explained by displacement of SHT from binding vesicles,
again with an increase in SHT turnover (therefore, no
change in SHT levels).

Either case would require that

the catecholic THIQ would be taken up into SHT neurons.
This is further evidence of a structure-activity relationship between SHT and isoquinolines.
DOPAC levels in the hypothalamus were decreased
by all of the THIQs (but not the DHIQ) examined, with
generally no change in HVA levels, the exception being
3-CSAL, which also decreased hypothalamic HVA.

One

would suspect that these decreases reflect inhibition
of DA turnover.

Inhibition of TH, the rate limiting

step in CA synthesis, by isoquinolines have been demonstrated both in vitro and in vivo (171 - 173).

---

If MAO

inhibition were responsible for DOPAC decrease, one
would expect to see a concomitant decrease in HVA as
seen in the case of pargyline pretreatment (Table 8) .
4.

Carboxylated Isoguinolines Cause Opposite Effects on DOPAC and HVA in the Hypothalamus and
Corpus Striatum
1-CSAL, .causes a corpus striatum-specific (23)

increase in DOPAC and HVA.

These concomitant in-

creases may reflect an increase in DA turnover.
3-CSAL on the other hand causes significantdecreases
in both DOPAC and HVA in the hypothalamus.

This, as
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stated above, could reasonably be due to inhibition of
MAO or a decrease in DA turnover in the hypothalamus.
5.

Summary
This study shows that various isoquinolines

have remarkably different effects on the levels of
SHIAA,DOPAC and HVA.

Moreover, the isoquinolines in-

duce different changes in the three brain regions
studied.

Further studies of isoquinoline interac-

tions with biogenic amine systems will help to interpret the mechanisms by which these interactions
occur.
E.

The Brain 0-Methylation Patterns of CatecholIsoquinolines Are Remarkably Different from
Those of Their Parent Amines
The in vivo stereoselective a-methylation of

the catechol isoquinolines differed dramatically
frpm their parent amines, demonstrating significant
( para)

7-0~ethylation.

These studies on the ster-

eoselective enzymatic a-methylation of simple catechol isoquinolines by brain COMT are particularly
relevant, because they were performed in vivo.

In

vitro experimental studies seldom permit the liberty
to quantitatively relate the actions of an extracted
enzyme to its activity in the intact system.

To

date, methods used to study the stereoselective
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a-methylation of THIQs by caMT have usually involved
the enzyme being isolated from cell extracts, "purified," and studied in an artifical medium.
Among the many problems associated with extrapolating in vitro results back to in vivo systems are
the differences seen between in vitro and in vivo
stereoselective a-methylation patterns of physiological substrates of CaMT (DOPA,Epi, NE, DA,
DHPG, etc.)

(229, 231).

D~PAC,

In vivo results have demon-

strated almost exclusive formation of the meta (3-0CH )
3
derivative (232) while conversely, in vitro results
have shown meta/para ratios that varied significantly
. h m1nor
.
.
.
w1t
c h anges 1n
pH, Mg++ concentrat1ons,
an d SAM

cofactor concentrations (231- 236).
The reasons for the anomaly between different
isomeric ring substitutions in vivo and in vitro are
not known.

It has been suggested that the differences

could be due to the cellular disruption which could
alter the native conformation of COMT.

The direct

in vivo investigations in this dissertation circumvent these complications by allowing substrate-enzyme interactions to occur while maintaining the microenvironment of the biological system under investigation.
The catecholic THIQs have been shown to interact
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with CaMT as competitive inhibitors in vitro (151 - 153)
and in vivo (153, 237), and, furthermore, undergo a-methylation (148, 151, 153).

However, the elucidation of

the a-methylated products in vivo had not been accomplished.

In vitro studies, utilizing purified rat

liver CaMT to determine the stereoselective a-methylation of 6,7-dihydroxy THIQ, N-Methyl 6,7 dihydroxy
THIQ (154}, THP and THPB (156}, demonstrated significant para (7-aca ) a-methylation.
3

In light of the

known lack of agreement between in vivo and in vitro
CA results, these findings with THIQs have to be
viewed with caution in regard to their physiological
relevance.
To date, the only studies on in vivo a-methylation of THIQs in tissues, particularly brain, was forwarded by Bail et al.

(155).

Their studies presented

chromatographic evidence indicating that the a-methylation of (+) SAL and (+) 6,7(aH)

2

THIQ in the rat CNS

were predominantly on the "para" (?-position) hydroxyl.
These results were unexpected because, as reviewed,
endogenous CAs are primarily or exclusively a-methylated in vivo on the meta (3-aH) hydroxyl.

Bail

et al. were unable to definitively separate and
quantitate the two a-methylated SAL and 6,7-(aH) 2
THIQ products due to lack of chromatographic
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resolution.
Our results unequivocably demonstrate that the
a-methylation of THIQs in vivo follows discrete patterns that are very different from the CAs.

In fact,

no catechol substrates have ever shown the high degree of p-a-methylation like SAL and 1-CSAL.

DA

a-

methylation was observed to occur exclusively on the
meta (3} hydroxyl, thus confirming literature indications and insuring that the "variant" a-methylation of the THIQs was not an artifact of administration.
The reasons for the observed differences in the
stereoselective site for a-methylation between precursor CAs and product THIQs in vivo are worth considering at this point.

Much evidence suggests that a

single enzyme catalyzes the formation of both a-methylated products from catechols (229}.

Extensive purifi-

cation of CaMT did not affect the meta/para ratio of a
variety of substrates, providing further evidence that
only one enzyme is involved in both meta and para

a-

methylation of catechols (238}.
The ratio of meta and para a-methylated products
in vitro was found to be strongly dependent on the nature of the aromatic substrate and the pH of the reaction medium.

Meta-(3}-0-methylated isomers predomi-

nated with substrates which contained highly polar
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substituents [as is the case with physiological substrates (154)], while substrates with non-polar substituents had ratios close to unity.
There are at least two possible explanations for
the negative effects of polar substituents on p-0-methylation by COMT (231):

a) Catechols containing sub-

stituents with highly polar moieties are bound by means
of this highly polar substituent in an orientation that
favors transfer of the methyl group to the meta (3) position, or, b) A hydrophobic region is present in the
active site of COMT which prevents random binding of
polar substrates by repulsive interactions so that
binding occurs primarily (as is the case of physiological substrates) in a conformation which favors meta
a-methylation.

Since the apparent affinity of polar

substrates for COMT does not differ markedly from
those of non-polar compounds, and since both anonic
and cationic polar substituents have the same effect
on p-methylation, the latter explanation is favored.
The presence of a non-polar region in the catechol binding site of COMT would then militate the
orientation of binding, directly influencing
meta/para ratios.

The meta/para ratios obtained

with amine substrates would be due to the presence
of the ionized ammonium function in the side chain
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being oriented away from this non-polar region.

Simi-

larly, studies utilizing analogues of DA and NE suggest meta/para ratios as a function of side chain interactions with hydrophobic centers on COMT (239).
charged

species on the substrate molecules would be

steered away from the hydrophobic centers, resulting
in binding orientations which would result in a stereospecific a-methylation reaction.
Application of these in vitro findings to the
in vivo results on THIQ stereoselective 0-methylation
can help to provide an explanation for the patterns
observed.

The THIQs, although structurally very

similar to CAs (having several structure-activity
relationships~

larity.

have one major structural dissimi-

The amine substituent is not flexible but

is fixed within a heterocyclic ring in the THIQ.
This limits the freedom of rotation of the amino
functional group (as well as other side chain substituents) and restricts the number of orientations
which the side chain can accommodate.

This restricted

movement of ionizable groups adds another parameter
to the binding orientation of THIQs to COMT.
Figure 57A illustrates the manner in which a
hydrophobic region adjacent to the active site of
COMT could influence binding orientation of
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physiological substrates.

The hydrophobic area orients

the ionized side chain such that binding of substrate
best accommodates the charge species outside of the
hydrophobic area.

Binding such that the para hydroxyl

is a-methylated is possible but involves overcoming
hydrophobic forces.

The THIQs would be particularly

susceptible to hydrophobic steering of their ionizable
substituents because of the additional loss of rotational freedom due to the heterocyclic ring.

The

most favored orientation would, as in the case of CAs,
place charged substituents outside this hydrophobic
area (Fig. 57b).
Utilizing the above rationale, the observed
stereoselective binding of the THIQs assayed in this
dissertation can be understood.
R =cH ), which was a-methylated to a major (95%) ex2
3
tent on the para-7- hydroxyl, had to bind in an upside-down orientation in relation to CA binding.
Thus, the charged amine was positioned away from the
hydrophobic center while the hydrophobic region of SAL's
ring was oriented into the hydrophobic center.

The

5% meta binding observed may be due to R (cH ) being
1
3
able to interact with the hydrophobic region thus
deferring some of the hydrophobic repulsion forces.
This is a tenable explanation in light of
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the results with (+} 1-CSAL (R =COOH, R =CH , R -R =H}.
3
3 4
1
2
The presence of carboxylic acid moiety on the R sub1
stituent eliminates a "meta-wobble" and militates
strict (100%}

"para" (7-0H) 0-methylation.

Binding

orientation places both the charge amine and carboxylic
acid away from the hydrophobic center, thereby positioning the para-hydroxyl for methylation.
4,6,7-(0H)

3

THIQ (R =R =R =H, R =0H) has polar
4
1 2 3

substituents located in a meta orientation to one
another and may therefore represent a class of THIQ
substrates with intermediate binding specificity.
Binding in either the meta or para orientation positions places a polar moiety within the hydrophobic
region.

This is reflected in the observed (55% meta/

45% para) randomized product ratio.

Similarly,

(-)

3-CSAL (R -cH ,R R =H R =COOH) has two (2) polar
3
3 2 4
1
moieties (located ortho to one another).

Binding of

the substrate in the para orientation brings the carboxylic moiety in close proximity to the hydrophobic
region.

Binding in the meta position would bring

the amine within proximity of the hydrophobic region
but also positions the R methyl group in a favorable
1
position for overlap with the hydrophobic center.

The

binding is randomized but favors the accommodation of
the methyl group overlap and yields 60% meta/40% para
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results.
1-Me-6,7-DHIQ represents a novel finding in that
it appears not to undergo
tectable extent.

a-methylation to any de-

As described (vide supra in section

D2) this compound resides in a quinoidamine conformation and resembles the tropolone-like inhibitors
of COMT.

The tropolone-like inhibitors compete with

CAs for the active site of caMT, but are not metabolized (233, 240)

(Fig. 56).

The lack of a catechol

moiety at physiological pH is no doubt responsible
for the inert nature of these compounds toward enzymatic a-methylation.
An additional set of interesting observations
can be gleaned from these results.

In Tables 4, 5,

and 6 the % a-methylation and the levels of catechol
isoquinolines

(~g/g

brain region) are given

as found in the corpus striatum, hypothalamus and hippocampus, respectively.

The levels of the catechol

isoquinolines appear to be similar in both the corpus
striatum and hippocampus.

However, the % a-methyla-

tion for the carboxylated-THIQs is consistently
lower.

In the corpus striatum (Table 4) 1-CSAL is

66% of SAL while 3-CSAL is 33% of SAL.

In the hypo-

thalamus (Table 5) the levels of carboxylated THIQs
are 2 - 2.5 fold that of the noncarboxylated THIQs
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and the % a-methylation is found to be approximately the
same.

In the hippocampus (Table 6) the levels of 3-CSAL,

sAL, and 4,6,7-(0H) 3 THIQ are similar.

However, the%

a-methylation for the carboxylated THIQ is 37% of the
non-carboxylated THIQs.

These results may reflect a dif-

ference in the Km's between the carboxylated and noncarboxylated THIQs.

These results again reflect signi-

ficant differences between the THIQs and the open chain
catecholic substrates which bear acidic, neutral, and
basic constituents whose Km's are not markedly different (231).

If this is the case, the presence of a car-

boxylic acid moiety on the side of a THIQ would result
in an extended T 1/2.

The consequence of this increase

in T 1/2 would be a similar increase in the duration
of the pharmacological effect.
F.

a-Methylation of a Catechol Isoquinoline Increases Its Half-Life in Brain Over 10-Fold
and Alters Its Effects on Biogenic Amine Systems

1.

Centrally Administered 7M-SAL Significantly
Affected the Levels and Turnover of Regional
Brain Biogenic Amines and Acid Metabolites
The phenolic isoquinoline 7M-SAL tended to in-

crease SHIAA without increasing SHT in hypothalamus
and hippocampus over the entire 48 hr period assayed
(Fig. 44).

Striatal increases in SHIAA, HVA, and
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oOPAC levels were restricted to the first 24 hr.

These re-

sults, increased acid metabolites with no concomitant increases in biogenic amine levels, indicates that 7M-SAL
increased biogenic amine turnover in all three tissues
assayed.

This represents an obvious change in the pharma-

codynamics of SAL upon a-methylation.

The most signifi-

cant effect is on striatal HVA levels within the first
12 hrs after ICV administration.

In contrast to SAL

whose main effect is on 5HT neurons, 7M-SAL appears to
effect both 5HT and DA neurons, not as inhibitor of biogenic amine metabolism, but as an activating agent.
These effects indicate that the production of endogenous
catechol isoquinolines, followed by metabolism to their
phenolic "metabolites," would result in a complex array
of metabolic consequences.
2.

0-Methylation of a Catechol Isoquinoline Increases Its T 1/2 in Brain Over 10-Fold
ICV administered 7M-SAL had a calculated T 1/2

of 133 minutes as measured from its disappearance from
the corpus striatum and hypothalamus.

This repre-

sents a 10.6 fold increase in the T 1/2 of SAL in
the rat CNS.

SAL rapidly disappears from the CNS

with aT 1/2 of 12.5 min (150).

The T 1/2 was doubled

when pyrogallol, a known inhibitor of COMT, was administered, indicating that the disappearance of SAL
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is the result of conversion to an a-methylated metabolite.

Hamilton et al.

(13) provided the chromato-

graphic evidence for a-methylated SAL (isomer unknown)
in the CNS of mice treated with chronic EtOH.

In light

of the relative inertness of SAL to enzymatic oxidative degradation, a-methylation appears to be a major
metabolic pathway.

The consequences of a-methylation

in the case of SAL do not appear to be deactivation.
In fact, a growing body of evidence is challenging
the initial premise that a-methylation is totally
a deactivation process.

Recent findings have demon-

strated that 3M-DA, the primary in vivo product of DA
a-methylation by COMT, is not pharmacologicallyinactive compound.

Rats treated with 3M-DA exhibited

psychomotor effects which mimic those of DA treatment
in combination with MAO inhibitors, conditions resulting in increased 3M-DA formation (241).
G.

Catecholic and Phenolic 1-Me-DHIQs:

Spectro-

photometric, Fluorescence and Voltarnrnetric
Investigations Provide Interesting Results
1.

Spectrophotometric and Fluorescence Assays Indicate that 6-0H-DHIQs Are in the Quinoidamine Conformation at Physiological PH
At physiological pH (7.4), 1-Me-6,7-DHIQ and

l-Me-7M-DHIQ are totally in the quinoldamine
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conformation.

The interpretation of U V

and fluores-

cence results on 1-Me-DHIQs obtained in this dissertation were based to a large extent on the work of G.
Jonsson with HCHO generated DHIQs (lacking the 1-Methyl group)

(242, 243).

Jonsson's U V

and fluorescence results utiliz-

ing 6-hydroxy-DHIQ are identical to those generated
in this dissertation for 1-Me-6,7-DHIQ and l-Me-7MDHIQ.

Jonsson found that at pH 2.0, 6-hydroxy-3,4-

DHIQ showed two absorption peaks, one at 236 nm and
the other at 323 nm (242).

Above pH 6.0 - 6.5 the

spectra showed typical drastic changes with an appearance of a strong absorption peak at 365 nm.

This peak

increased with increasing pH, reaching a maximum at pH
8.0 - 9.0.

Above pH 9.0 the absorption gradually

decreased and at pH 13 the absorption characteristics
were similar to those of pH 2.0.

The 6-hydroxy-3,4-

DHIQ exhibited only weak fluorescence at low pH's
but fluorescence increased with increasing pH, reaching a maximum at around pH 8.0.

Above pH 8.0, the

fluorescence intensity fell, becoming very weak above
pH 12.0.
The 6-hydroxyl-3,4-DHIQ, lacking a 7-position
hydroxyl, by default, must form a tautomeric quinone
whose structure resembles form B (Fig. 45).

l-Me-7M-DHIQ,
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with a blocked 7-hydroxyl, behaves like its dihydroxy
derivative, which in turn behaves like 6-hydroxy-3,4DHIQ.

All three compounds show identical pH dependent

spectral changes.

The disappearance of long wavelength

absorption above pH 8.0 is probably due to the ionization of the hydroxyl group in the 6 position (Fig. 58A).
1-Me-6,7-DM DHIQ and l-Me-6M-DHIQ both have the
6-hydroxyl group blocked and behave almost identically.
Their typical spectral changes prevalent above pH 7.5
are probably due to addition of water across the imine
double band to form a carbinolamine (Fig. 58b)

(244).

Therefore, these results demonstrate that 1-Me6,7-DHIQ and l-Me-7M-DHIQ at physiological pH and ambient temperature exist in a quinoidamine conformation which bears structural similarities to the oxidized (apparent neurotoxic)

form of 60HDA (Fig. 19).

Previous results (section E) indicate that 1-Me6,7-DHIQ does not undergo a-methylation and that its
possible THIQ precursors (SAL and 1-CSAL) are both
0-methylated predominantly on the 7-position hydroxyl.

Therefore, even if the dihydroisoquinolines

were to be formed after a-methylation of the precursor THIQs, quinoidamine formation would not be blocked
by a-methylation.
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2.

Cyclic Voltammetry of 1-Me-6,7-DHIQ l-Me-7M-DHIQ
and l-Me-6M-DHIQ Indicate that They Are Irreversible Oxidized
Cyclic voltammograms of the DHIQs, 1-Me-6,7-DHIQ,

l-Me-7M-DHIQ and l-Me-6M-DHIQ demonstrated irreversible
oxidation throughout a range of pHs.

This is strik-

ingly different from the cyclic voltammetry of CAs,
THIQs, or 60HDA-like compounds, and suggests that the
electrochemical oxidation of DHIQ leads to the formation of an "atypical" product.

In order to facilitate

the interpretation of the results of the cyclic voltammetry of the compounds of interest, a brief discussion of cyclic voltammetry follows.
In voltammetry, a varying potential (Eapp) is
applied between a working electrode and a reference
electrode immersed in a quiet (non-stirred) solution
containing an electroactive component suspended in
a buffer.

The buffer, a supporting (background)

electrolyte is simply one which can provide overall
high conductance, while not being electroactive in
the region of interest.

The cut-off potential for

any voltammetric analysis is that potential where
general electrolysis of solvent begins to occur.
The working electrode is an inert surface which
serves as a source or sink of electrons.

As Eapp
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varied, molecules near the electrode surface can either
gain electrons from the source (cathodic reduction) or
loose them to the sink (anodic oxidation) .

Diffusion

occurs as a result of the concentration difference developed between the electrode surface and the bulk of
the solution as soon as electrolysis is initiated.
Diffusion is the predominant form of mass-transport
in quiet (standing) solution voltammetry.
When a working electrode is placed in a quiet
solution and Eapp is varied in a linear fashion (a
linear potential sweep) the response is a peak voltammogram (Fig. 59a) .

Figure 59a represents a model com-

pound whose oxidation occurs at Ep of 0.42 volts and
the magnitude of Ip is directly proportional to the
concentration of the compound in solution.

By con-

vention, oxidation currents are plotted downward
from the zero current line and the potential, E, is
increasing anodic or oxidizing, from right to left.
Potentials in voltammetry are usually referred directly to the experimental reference electrode, in
the case of our work, an Ag-AgCl electrode.
When a peak voltammetry is seen and the potential sweep is rapidly and reproducibly reversed, a
cyclic voltammogram is generated (Fig. 59b).

Since

the solution is quiet and the time interval between
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sweep reversals is short, the products generated in the
oxidation are available near the electrode for reduction as the potential sweep reverses.

In a simple,

rapid electron transfer, with no chemical complications, one obtains oxidation and reduction peaks whose
potentials are separated by a small increment as defined by equation:

- E
Pred

=

0 57
·
volts (245}
N

(Eq.

1}

The reversibility of any electron transfer can
be qualitatively judged by the separation of the oxidation and reduction peaks (Fig. 60}.

Figure 60a illus-

trates a fast (reversible} electron transfer; B, a less
reversible (quasi-reversible} transfer; while C, a slow
electron (irreversible} transfer.
In Figure 59b, the theoretical voltammogram for
a pure reduced species in solution is shown.

As can

be observed, it represents a reversible electron transfer system.

The potential sweep is initiated in an

anodic (oxidizing} direction at some arbitrary point.
During the time interval of peak b, the originally
fully reduced compound is oxidized.

At an arbitrarily

chosen point, the potential is reversed and peak a is
generated and represents the re-reduction of the compound.

With no intervening chemical reactions, the
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properly measure ratio of a/b currents is unity (246).
All the adrenergic NTs and their metabolites
(247), as well as the THIQ alkaloids, SAL and 0-Me-SAL
(248), possess electrochemical activity with their
voltammograms showing that they are quasi-reversible
systems.

60HDA, on the other hand, is a model com-

pound for cyclic voltammetry and displays near perfect reversibility (246).

It was unexpected to dis-

cover that the cyclic voltammograms of 1-Me-6,7-substi tuted- 3, 4·-DHIQs resembled neither the THIQs nor
CAs, their purported precursors, or 60HDA, to which
they bear some structural resemblance, at any of the
pHs tested.

Rather, the cyclic voltarnmograms of the

DHIQs demonstrated an irreversible electron transfer
system which could only undergo oxidation.

(The re-

duction peak is so negative and flat it could not be
distinguished over the reduction of the support solvent.)

The interpretation of these results possibly

would constitute detailed information regarding the
possible reactions and metabolic degradation of DHIQs
at the molecular level.
Aside from the pH-dependent decrease in oxidation potential (Table 14}, the cyclic voltammograms
were idential for all three DHIQs tested.

This would

indicate that upon electrochemical oxidation they are
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all being converted to the same product.

The primary

step of the oxidation was probably conversion to the
ortho-quinone similar to what is seen with CA oxidation.

One possible explanation is that the orthoquin-

one is an unstable intermediate which undergoes spontaneous intramolecular oxidation/reduction to yield
a fully aromatic, heteroaromatic molecule (Fig. 61}.
This would be similar to the internal oxidation reduction of cyclized 60HDA to form 5,6-dihydroxyindole

(249}.

Attempts to reduce the fully aro-

matic molecule would be futile, owing to its internal
reduction upon aromatization.

Any attempts to reoxi-

dize the "fully aromatic" heteroQaromatic species
would probably require very high electrochemical oxidation potentials to overcome the loss of aromaticity
upon oxidation.

This would account for the lack of

a new oxidation peak when repetitive sweeps were run
at applied potentials between (+} 1.2 and (-) 1.2 volts.
H.

Oxidative Decarboxylation of 1-CSAL to a DHIQ
or THIQ Appears to be Insignificant in the Normal
Intact Rat
As reported in the Results, detectable levels of

1-methyl-DHIQs were not observed after chronic i.p.
administration of 1-CSAL.

However, recently it has

been demonstrated that 1-carboxylated THIQs can be
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decarboxylated to their corresponding 3,4-DHIQs by
anodic oxidation at a low potential (184), prolonged
aerial oxidation in basic media (183), and exposure
to plant laccases and peroxidases (78).

In all the

oxidative decarboxylations a free'phenolic group at
position 6 or 7 of the isoquinoline system is essential.

These reactions are considered to be decar-

boxylations induced by oxidation of the phenolic hydroxyl group.

To date, no in vivo or in vitro decar-

boxylations of 1-carboxylated THIQs have been reported
using animal tissue, and initial experiments presented
here were unsuccessful.

This may be due in part to

rapid a-methylation and conjugation which is known
to occur with other THIQs.
a-methylation of 1-CSAL, as reported earlier
in this work was found to be predominantly on the
7-hydroxyl in brain (4-hydroxyl of the precursor
moiety) and was qualitatively observed on the 7-hydroxyl in liver.

These results imply that a signi-

ficant metabolic route for 1-CSAL is a-methylation.
Studies utilizing

trimetoquinol (TMQ), a cate-

chol THIQ having potent bronchodilating action, demonstrated that 61% of the excreted TMQ was conjugated
to glucuronide, 11.5% the free base, and 27.5% as amethylated-conjugated TMQ (222).

Further studies
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determined that sulfate conjugation of biogenic amines
and their acid and a-methylated metabolites is an important metabolic pathway in their metabolism in the
eNS {250 - 251).

These reactions would tieup the

free phenolic hydroxyls of THIQs {necessary for oxidative decarboxylation) thereby deactivating the
THIQs toward oxidative decarboxylation.
Alternatively, the optimum situation for the
formation of DHIQs from THIQs in the rat in vivo may
be after chronic EtOH or barbiturates when microsomal
oxidizing systems are "induced."

In an analogous

situation, Dajani and Saheb (252) , studying the metabolism of 6-hydroxy- and 6-methoxy-1,2,3,4-tetrahydroS-carbolines (THBCs), found that varying metabolic
conditions favored the formation of a number of oxidized S-carbolines both in vivo and in vitro.

These

findings give rise to yet another alternative explanation, that is, formation of other oxidative products
such as N-oxides and fully aromatic isoquinolines
(Fig. 62).

Hamilton and Gause (253) have indicated possi-

ble formation of N-oxides from SAL and 6,7-(0H) -THIQ
2
after incubation in mild aqueous alkaline conditions.
Results of the cyclic voltammograms generated in this
dissertation indicate the possible formation of fully
aromatic isoquinolines upon oxidation of DHIQs.

These
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alternative oxidation products may have formed but would
not have been detected because those possible products
were not available as standards.

r.

Simple 6-Hydroxy-DHIQs Do Not Apparently Form
Glutathione Adducts
CAs after oxidation to ortho-quinones as well

as 60HDA, 6-amino-DA (6NH 2 DA) and their analogues,
after oxidation to para-quinones, are known to undergo
irreversible nucleophilic additions of sulfhydroryl
compounds (190, 249, 254).

The addition of thiol

to carbon-carbon double bonds of a quinone constitutes
a special case of nucleophilic addition to an
saturated system (255).
reactions is R-S-H.

~-S-un

The nucleophile in these

The reaction occurs rapidly

when the electron density of the carbon-carbon double
band is reduced by electron withdrawing substituents
(256).

Electron withdrawal can be either by induc-

tion or resonance, or both.
We can conclude that simple 1-akyl-6-hydroxy7-alkoxy-substituted-3,4-DHIQs, which at physiological pH reside as para quinoidamine tautomers, do
not participate to any detectable extent in sulfhydryl adduct formation.

The plausible explanation

for this lack of reactivity may lie in the low electrophilic character of tautomeric double bands.
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unlike the para-quinones of 60HDA and 6NH DA which can
2
rely on the strong electron withdrawing capacities of
two electron withdrawing substituents, the DHIQs tested
have only the proximal catecholic oxygen which cannot
sufficiently reduce the electron density of the double
band participating in adduct formation.

(The distal

atom in the para-quinone being the 1-carbon; carbon
atoms are poor electron withdrawing groups.)

However,

the electrophilicity of the DHIQ tautomers can be enhanced if the 1-methyl substituent would be replaced
with an electron withdrawing group.

This is the case

when dealing with one of the DHIQ products of oxidative decarboxylation of 1-carboxy-1-benzyl THIQs.
These THIQ compounds, as noted in the introduction,
are present in various pathological conditions (3, 7),
and are known to undergo oxidative decarboxylations under a variety of conditions (78, 183, 184)
to form

~-keto-'3,'4-substituted-1-benzyl-6,7-substi

tuted DHIQs.

These compounds may be electrophi-

lic enough to undergo adduct formation through the
enhanced electron-withdrawing capabilities of the
a-keto and 1-benzyl substituents.

If these complex

DHIQs share even a degree of the electrophilic
character of 60HDA quinone, they should be capable
of producing neuronal damage via covalent attachments
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to cellular nucleophiles.
J.

Ethanol and Acetaldehyde in Human Blood
GC methods for the determination of EtOH and AcA

are specific, sensitive and rapid.

However, an acknow-

ledged problem hindering the precise measurement of AcA
and EtOH containing samples (blood and tissues) is artifactual (non-enzymatic) generation of the aldehyde
(257).

It has been reported that addition of 20- 40

mM thiourea suppressed AcA production from EtOH in deproteinated rat blood which was incubated at 65°C, but
that thiourea was only partially effective when human
blood was used (258).

We found, however, that arti-

factual AcA formation was essentially absent of human
blood sample in perchloric acid and thiourea were incubated at a lower temperature.

As would be expected,

incubation at a lower temperature lowered AcA and
EtOH recoveries.

However, the recoveries were ade-

quate to permit minimum detection of 0.04 mg/dl of
AcA.
The significant importance of this portion of
the study is that mean blood AcA concentrations did
not remain elevated throughout the four day detoxification period.
et al.

An earlier report by Magrinat

(207) stated that blood AcA concentrations

in patients admitted for alcohol detoxification
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remained at admission day levels over four days as blood
EtOH dropped to negligible values.

Our findings show

that blood AcA levels drop 70% within one day after admission and were undetectable on days 2 - 4.

The pos-

sible differences in subject population, previous alcohol or drug consumption, or nutritional and hepatic
status should not account for this large disparity
with regard to blood AcA concentration on days 1 - 4
of detoxification.

A possible conclusion for the

chronically elevated blood AcA levels reported earlier
in detoxification is that the workers failed to account
for artifactual AcA formation during analysis.

CHAPTER V
SUMMARY
In this dissertation, relatively simple, highly
sensitive, and specific techniques were developed or
improved for use in neurochemical studies of tetrahydroisoquinoline metabolism.

A direct assay of tissue

supernatants by high performance liquid chromatography
with electrochemical detection was used to measure
tetrahydroisoquinolines, biogenic amines and acids in
small brain samples.

Capillary gas chromatography

with electron capture detection proved to be a very
selective and extremely sensitive approach to the estimation of biogenic amines and catechol isoquinoline
stereoisomers in discrete brain regions.
Utilizing the highly sensitive (minimal detectable quantity for salsolinol and 0-methylated products,
3 - 5 ng/g) gas chromatography with electron capture
detection assay developed in this dissertation, it was
found that salsolinol in low peripheral doses (5 -

20

mgjkg) was not taken up into the central nervous system.
These results are additional support that salsolinol and 0-methylated-salsolinol, detected in the
central nervous system of experimental animals after
126
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ethanol administration, were derived in situ and were
not the result of peripheral formation followed by
uptake.
Centrally administered catechol isoquinolines
(10 - 50

~g)

were found to alter the steady state

levels of biogenic amines and acid metabolites to differing degrees, depending on the isoquinoline and the
brain region.

Of particular interest was the effect of

catechol isoquinolines on the serotonergic system.

A

variety of catechol isoquinolines raised the steady
state levels of serotonin, indicating that as a class
these compounds can interact, indirectly and/or directly, with serotonergic systems in vivo.

The iso-

quinolines could thus serve as neuromodulating bridges
between catecholaminergic

systems and serotonergic

systems.
The a-methylation patterns of several centrally-administered catechol isoquinolines were found
to be different from those of their parent amines, as
reflected by the extent of a-methylation on the 7-position hydroxyl (para position in the parent catecholamine) .

Such in vivo studies on the stereoselec-

tive enzymatic a-methylation of simple catechol isoquinolines are more relevant than in vitro approaches,
because substrate-enzyme interactions occur in the
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endogenous microenvironment of the biological system
under investigation.
The endogenous half-life of centrally administered 7-0-methyl-salsolinol (salsoline; the major methylated metabolite of salsolinol in vivo) was determined to be 133 minutes in two brain regions, the
striatum and the hypothalamus.

This represents a 10.6

fold increase over the reported half-life of the parent
isoquinoline salsolinol.

In addition, salsoline was

found to effect the steady state levels of biogenic
amines and acid metabolites

over a 48 hour period.

These effects, increase in half-life and pharmacological
activity of an a-methylated metabolite, indicate that
production of endogenous catechol isoquinolines followed by metabolism to phenolic metabolites would result in a complex array of metabolic consequences.
Spectrophotometric studies of 1-methyl-6,7-substituted 3,4-dihydroisoquinolines (potential products
of tetrahydroisoquinoline oxidative metabolism) indicated that, at physiological pH, those with 6-hydroxysubstituents are nearly exclusively in the quinoidamine conformation (the conformation postulated for
nucleophilic attack on cellular ligands) .

The cyclic

voltammetry of these dihydroisoquinolines showed that
upon electrochemical oxidation they become irreversibly
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oxidized, suggesting transformation to a fully aromatic
species.

1-methyl-6-hydroxy-7-alkoxy-substituted-di-

hydroisoquinolines apparently do not readily form glutathione adducts as such.
simple

Also, in vivo synthesis of

1-methyl-dihydroisoquinoline~

salsolinol (injected chronically)

from 1-carboxyl-

by oxidative decar-

boxylation,appeared to be insignificant in the normal
intact rat.
These findings represent advancements in our
knowledge about the discrete metabolic consequences
of catecholamine-related isoquinolines in mammalian
systems, advancements which could aid in understanding
the underlying meaning of condensation product involvement in mammalian homeostasis and disease.

Table 1
Selected Physical Data for Synthesized
Compounds in Section II
Compound

M0

MP°CB

Salsolinol HBr (SAL)

264

183 (lit. 182-184)

1-Carboxy-Salsolinol (1-CSAL)

223

233 (lit. 230-235)

7 -0-Hethyl-1-Carboxy-Salsolinol (7M-l-CSAL)

237

205 (lit. 205)210

6,7-Dihydroxytetrahydroisoquinoline (6, 7-(0H) THIQ) HB.r 250
2

268 (lit. 267-268)

1-Methyl-6,7-dihydroxy-3,4-dihydroisoquinoline
(1-Me-6,7-DHIQ HBr)

230 (lit. 230)259

"'

r.~..WJ

=

BMP o C

263

% Yieldc

208
208

85
94
85

209

80
90

Molecular weight (salt) •
'
= me 1t1ng

c% Yield

.
d egrees centlgra
.
d e.
po1nt

actual yield
X lOO.
theoret1cal y1eld
1-'

w

0

Table 2
Summary of GC Capillary Parameters for
Selected Compounds of Interest
Compound

Column Temp

0

c

Retention time (min) a

Derivative

(b)
MDQ
_(ng/m1)

DHBA

130

4.00

HFBA

DA

130

6.00

HFBA

0.25

3M-DA

130

9.50

HFBA

0.45

4M-DA

130

10.20

HFBA

0.45

SAL

130

8.40

HFBA

0.25

6H-SAL

130

21.55

HFBA

0.45

7M-SAL

130

22.55

HFBA

0.45

4,6,7(0H) THIQ
3

130

12.05

HFBA

2.00

6M-4,7(0H) THIQ
2

130

17.64

HFBA

5.00

7M-4,6(0H) THIQ
2

130

18.80

HFBA

7.00

1-CSAL

125

6.45

PFPA/HFIP

1.00

6M-l-CSAL

125

16.20

PFPA/HFIP

5.00

7M-l-CSAL

125

18.16

PFPA/HFIP

5.00

t-'

w

I-'

Table 2 (Cont'd)
Summary of GC Capillary Parameters for
Selected Compounds of Interest
Compound

Column Temp

0

c

Retention time (min)a

Derivative

MDQ (b)
(ng/ml)

3-CSAL

155

5.40

PFPA/HFIP

1.00

6M-3-CSA.L

155

16.70

PFPA/HFIP

5.00

7M-3-CSAL

155

19.25

PFPA/HFIP

5.00

1-He-6,7 DHIQ

145

4.55

HFBA

1. 00

l-Me-6M,70H-DHIQ

145

7.10

HFBA

7.00

l-Me-7M,60H-DHIQ

145

8.50

HFBA

2.00

alOM X.25mm i.d. OV-17 glass NCOT capillary column N °2F 0.8 kg/cm
2
340, injector temperature 250°C.
b

2

detector temperature

Minimum detectable quantity (equivalent to twice the baseline noise).

1-'

w
N

Table 3
Summary of Retention Timesa and Selected HPLC Parameters
Retention Times (min)
Co!" pound

6mM Heptane Sulfonic Acid,
10% MeOH, 9.7% HOAct pH 3.5

O.lM NaH Po ( l.OmM Na EDTA
2 4
2
pH 5.0

NE

6.2

1.9

DHBA

8.1

3.9

10.4

5.2

4.9

6.8

21.8

13.6

8.1

17.6

HVA

11.3

20.1

SAL

12.0 (8.40)b

8.4

6r1-ST•L

(27.0)b

22.8

7M-f.:AL

(23.4)b

22.8

DA
DOPAC
5HT
5HIAA

4,6,7-(0H) THIQ
3

4.0

6M 4,7-(0H) THIQ
2

9.2

7M 4,6-(0H) THIQ
2

11.6

f-'

w
w

Table 3 {Cont'd)
Summary of Retention Timesa and Selected HPLC Parameters
Retention Times (min)

Compound

6ml'1 Heptane Sulfonic Acid,
10% MeOH, 9.7% HOAc, PH 3.5

1-CSAL

.1M _ NaH Po ; .lmM Na EDTA,
2 4
2
pH 5.0
4.0

6!11-l-CSAL

12.8

7M-l-CSAL

16.2

3-CSAL

4.4

6H-3-CSAL

14.4

7M-3-CSAL

16.0

1-Me-6, 7-DHIQ

(12.86)c

l-Me-7M- DHIQ

(l8.60)c

1-Me- 61',1- DH IQ

(39.60)c

1--'

w

~

Table 3 (Cont'd)
Summary of Retention Timesa and Selected HPLC Parameters
Retention Times (min)

aBiosil

c 18

reverse phase 25 em column, flow rate 1.0 ml/min.

bChromatographed using a O.lUN&H Po ,lmM Na~DTA buffer pH 5.5 with 5% MeOH.
2 4
cChromatographed using a O.lMNa~Po ,lmM Na2EDTA buffer pH 7.4 with 10% MeOH.

4

f-'

w

U1

Table 4
Stereoselective In Vivo a-methylation of Catechol
Isoquinolines in Rat Corpus Striatuma

% of Total Methylation

+ S.E.M.

Compound

(N

=

6)

%(b)
Levels of
6-a-methylation 7-a-methylation catechol isoquinoline a-methylation
precursor
(+ s.e.m.)
(~g/g:!:. s.e.m.)
5 + 1. 5

95 + 1. 5

18.0 + 0.98

18. 0 + 1. 30

4,6,7-(aH) THIQ
3

55 + 2.8

45 + 2.8

15.8 + 3.60

17.4 + 0.50

1-CSALe

N.d. (c)

o.o

19.7 + 3.90

12.0 + 1.60

28.3 + 4.80

6.0 + 0.70

SAL

100 +

e

60 + 1. 3

40 + 1.3

1-He-6,7-DHIQ

N.d.

N.d.

3-CSAL

DAd

(3M-DA 100

~

0.0)

(4M-DA N.d.)

I-'

w

())

Table 4 (Cont'd)
Stereoselective In Vivo a-methylation of Catechol
Isoquinolines in Rat Corpus Striatuma

a N

= 6.

b % a-methylated

c

=

N.d.

=

. Total
"'I

-- -

a-methylated product
-

•

•

•

..

-

•

•

..

•

X 100.
...

-- -

-

Not detectable.

d Pretreated with pargyline.

e N

=

4

.......

w

~

Table 5
Stereoselective In Vivo a-methylation of Catechol
Isoquinolines in Rat Hypothalamus
% of Total Methylation

+ S.F.M.
Compound

6-a-methylation

(N

=

6)

?-a-methylation

Levels of
catechol isoquinoline
precursor
11g/g :t s.e.m.

%b
a-methylation
<± s.e.m.)

6 + 1.1

94 + 1.2

22 + 1.4

17 + 2.0

4,6,7-(aH) THIQ
3
1-CSALa

57 + 2.0

43 + 1.0

34 + 1.8

13 + 3.0

60 + 7.2

12 + 1.1

3-CSALa

61 + 2.0

39 + 2.0

N.d. c

N.d.

SAL

1-Me-6,7-DHIQ
DAd

100 + 0

N.d.

(3M-DA 100

±

0)

69 + 12.2

9.8 + 2.5

(4H-DA N.d.)

1--'

w

co

Table 5 (Cont'd)
Stereoselective In Vivo a-methylation of Catechol
Isoquinolines in Rat Hypothalumas

a N

=

4.

b ~0 a-methylated

c

N.o.

=

-

.

Total
. - 0-methylated
- . . . - -

pr?d~c~
.

_

_ _ X 100.

Not detectable.

d Pretreated with pargyline.

I-'

w

~

Table 6
Stereoselective In Vivo a-methylation of Catechol
Isoquinolines in Rat Hippocampus

% of Total Methylation

+ S.E.M.
Compound

(N = n)

6-0-methylation

7-0-methylation

Levels of
catechol isoquinoline
precursor
JJg/g
s.e.m.

±

3 +

SAL

.5

97 +

16 + 2.6

19.6 + 2.0
18.6 + 1.5

54 + 1. 7

46 + 1. 5

19 + 2.6

3-CSALa

60 + 1. 3

40 + 1.3

14.5 + 7.5

DAd

a N

N.d.

c

3M-DA 100 + 0

=

(+ s.e.m.)

.5

4,6,7-(0H) THIQ
3

1-Me-6,7 DHIQ

%b
a-methylation

7.0 + 0.42

N.d.
4M-DA N.d.

3.

1-'

"""

0

Table 6 (Cont'd)
Stereoselective In Vivo a-methylation of Catechol
Isoquinolines in Rat Hippocampus

h

._ % a-methylation

c N.d.

=

=

rT"I

I

...

Total 0-methylated

rY'IYT"T""

t

I

I

.,

-

I,

..

I

~

............... -

X 100.

Not detectable.

d Pargyline pretreated.

1-'
~

1-'

Table 7
Survey Study of SAL Uptake into the Corpus Striatum,
Hypothalamus and Hippocampus after Intraperitoneal Administration (5-20mg/kg)a

Brain Region

Salsolinolb

Corpus striatum

N.d.

Hypothalamus
Hippocampus

a N

e

6M-Salsolinolc

Dopamine
± s.e.m.

\.19/9

N.d.

N.d.

9.50+ 0.78

N.d.

N.d.

N.d.

1.90 + 0.31

N.d.

N.d.

N.d.

N.d.

= 12.

b Minimum detectable quantity 3 ng/g

(17.3 pmoles/g).

c Minimum detectable quantity 5 ng/g

(28.6 pmoles/g).

d Minimum detectable quantity 5 ng/g

(28.6 pmoles/g).

e

7M-Salsolinold

N.d.

= Not detectable.

f-'
of:>,

N

Table 8
Levels of 5-HT and Acid Metabolites (Percent of Control)
in Brain Areas of Rats 50 Min after (ICV) Treatment
with Various Isoquinolines (50 llg)
HIPPOCA.111PUS
Compound

5-HT
-

5-HIAA

STRIATUM

HYPOTHALM1US

5-HIAA

DOPAC

HVA

5-HIAA

DOPAC

HVA

SAL

186*

110

97

99

93

111

73*

94

4,6,7-TIQ

145*

127*

82*

91

94

178*

77*

109

1-CSAL

112

94

103

160*

116*

150*

79*

103

3-CSAL

160*

92

83*

98

93

127*

67*

1-Me-6,7-DHIQ

176*

99

89

81*

148*

26*

18*

55*

39*

Pargyline/DA

--

* Significantly different from control (p<0.05)

111
29*

110
39*

63*
74*
90

1-'

""'
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Table 9
Effects of Catechol Isoquinolines on the Levels of 5-HT and 5-HIAA in the Rat Hippocampus
]Jg/g
5HT
-

Compound

tissue + s.e.m.
% ~

c

(N

=

6)

E.

5HIAA

--

0. 2 30 + .020

%C

E.

Control (saline)

0.352 + .040

--

SAL

0.656 + .090

186

.01*

{). 254

.040

110

NSD

4,6,7-(0H} THIQ
3

0.510 + .020

145

. 01*

0.292 + .040

127

. 01*

1-CSAL

0.359 + .060

112

NSDb

0.217 + .020

94

NSD

3-CSAL

0. 569 + . 0 80

160

,01*

0.211 + .020

92

NSD

-± .080

--

--

0.061 + .010

26

.01*

.01*

0.229 + .020

99

NSD

Pargyline/DA
1-He-6,7-DHIQ

0.618

176

a t1ale Sprague-Dawley rats were given one dose of catechol
(50 ug/animal} bilaterally into the cerebral ventricles.
with 50 mg/kg of pentabarbital i.p.
b NSD
c

%

= Not

c =

±

isoquinol~ne

o~ dopamine
All animalS were anesthetized

significantly different.

% of control.

1-'

"'"'""
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Table 10
Effects of Catechol Isoquinolines on the Levels of Acid Metabolites ef the
Biogenic Amines in Rat Striatum
tissue

± s.e.m.

% c

E

5HIAA
0.72 + .03

~g/g

Compound

DOPAC

%C

E

-- --

a

HVA
-

%c

E

Control (saline)

1.62 + .15

--

--

SAL

1.61 + .15

99

NSDb 0.70 + .06

4,6,7-(0H) THIQ
3

1.48 + .18

91

NSD

1-CSAL

2.59 + .13 160 .01*

0.74 + .04 103

3-CSAL

1.59 + .09

98

NSD

0.60 + .08

83 .02* 0.79 + .08

93 NSD

Pargyline/DA

0.47 + .10

29 . 01*

0.13 + .02

18 . 01* 0.47 + .07

55 . 01*

1-Me-6,7-DHIQ

1.81 + .36 111

0.64 + .09

89

NSD 0.69 + .12

81 .05*

NSD

0.59 + .07

0.85 + .05

NSD 0.79 + .07

93 NSD

82 .01* 0.80 + .07

94 NSD

97

NSD 0.99 + .04 116 . 01*

a Male Sprague-Dawley rats were given one dose of catechol isoquinoline or dopamine
(50 ~g/animal) bilaterally into the cerebral ventricles. All animals anesthetized
with 50 mg/kg of pentabarbital i.p.
b NSD

=

Not significantly different.

c ~ C

=

% control.

0

~

"'"

Ul

Table 11
Effects of Catechol Isoquinolines on the Levels of Acid Metabolites of
the Biogenic Amine in Rat Hypothalamus
~g/g

Compound

DOPAC

tissue
cc

%
- E
-- --

~

s.e.m.

a

(N == 6)

5HIAA

%C
-

0.323 + .010 --

HVA
-

E

--

%C
--

E

94

NSD

0.305 + .020

Control (saline)

0.114 + • 009

SAL

0. 083 + • 008

-

73 .01*

a. 358

+ • o3o 111 NSD ().287 ~ .006

4,6,7-(0H) THIQ
3

0.088 + .008

77 .01*

o. 57 5

+ • 0 4 0 1 7 8 .01*

+ .020 109

NSD

1-CSAL

0.090 + .004

-

79 .01*

0. 4 86 + • 0 30 150 • 01 'i• 0. 314 + .020 103

NSD

3-CSAL

o. 076

+ .009

67 .01*

o. 4 10 + • 0 10 12 7 .01* 0.192 + • 040

Pargyline/DA

o. 045

+ • 007

39 .01*

0.121 + .010

1-Me-6,7-DHIQ

0.125 + • 061

110

NSD

o. 333
I

37 .01* 0. 276 + • 050

0. 4 71 + • 0 50 14 8 . 0 1 * 0. 2 2 6 + • 0 2 2

a Male Spraque-Dawley rats were given one dose of catechol
(50 ~g;animal) bilaterally into the cerebral ventricles.
with 50 mg/kg of pentabarbital i.p.

63 .01*
90

NSD

74 .01*

is~quinoline

or dopamine
All animals were anesthetized

b NSD == Not significantly different

c

%c

== % of control

1-'
,j::>.
0)

Table 12
Effect of 7-0-Methyl-Salsolinol (lOug/rat) on the Levels of Biogenic
Amines and Acid Metabolites in the Rat Striatum
~g/g

Time of Sacrifice (hr)
Control

Dopamine
8.45 + 1.04

tissue

a

!._£__ P.

±

s ..e.m.

(N·

DOPAC

-- NSDbl 1.30 + .20

=

4)

%c

--

--1

HVA

%C

E

.626 + .036

1

8.60 + 0.49

101 NSD

3

8.80 + 0.64

104 NSD

6

8. 40 + 1. 24

99 NSD

1.45 + .09 111

NSDI 0.814 + .172 130 NSD

12

8.20 + 0.23

97 NSD

1.51 + .02 115

NSDI 0.836 + .058 133 .05*

24

9.30 + 0.67

110 NSD

1.18 + .12

90

NSDI 0.640 + .134 102 NSD

48

6.42 + 0.53

76 .02* I 1.17 + .08

90

NSDI 0.504 + .074

Time of Sacrifice (hr)

5HT

Control

%C

p_

0.518 + .052

I 1.43 + .17 109

P.

NSDI1.202 + .032 192 .01*

1.64 + .07 125 .05*11.016 + .088 162 .01*

5HIAA

%c

80 NSD

P.

0.366 + .027

1

0.482 + .060

93 NSD

3

0.544 + .048

105 NSD

0.351 + .019

96

NSD

0.509 + 0.25 139 .02*

f-'

""'
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Table 12 (Cont'd)
Effect of 7-0-Methyl-Salsolinol

(10 ug/rat) on the Levels of Biogenic

Amines and Acid Metabolites in the Rat Striatum
Jlg/g tissue + s.e.m. ~N

%c

SHIAA

=

4)

%c

Time of Sacrifice (hr)

5HT

6

0.516 + .046

99 NSD 0.454 + .042 124 .05*

12

0.400 + .034

77 .02* 0.418 + .017 114 .05*

24

0.458 + .050

88 NSD 0.344 + .042

94

NSD

48

0.454 + .032

88 NSD 0.344 + .046

91

NSD

E

E

---------------------------------------------------------------------------------------a % e·

=

% control.

b NSD

=

Not significantly different

1-'
CX>
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Table 13
Effect of

7-0-Methyl~alsolinol

(10 ug/rat) on the Levels of

5-R~

and 5-HIAA in Rat Hypothalamus (A) and Hippocampus (B)
ll gIg tissue

+ s . e . m. ( N .:. 4 )

Hypothalamus (A)
Time of Sacrifice (hr)
Control

5-HT

G

% c- p*

5-HIAA

%c

p*

0.448 + .024

0.606 + .034

1

0.644 + .090

106 NSDb

0.444 + .027

99 NSD

3

0.672 + .076

111 NSD

0.410 + .038

92 NSD

6

0.548 + .054

90 NSD

0.416 + .028

94 NSD

12

0.612 + .050

101 NSD

0.538 + 0.57

120 .05*

24

0.634 + .036

105 NSD

0.613 + .007

137 .01*

.48

0.584 + .058

96 NSD

0.561 + .035

125 .01*

Hippocampus (B)
Time of Sacrifice

5-HT

% c

p*

5-HIAA

% c

p*
1-'

Control

0.295 + .011

0.299 + .025

ol:lo

1.0

Table 13 (Cont'd)
Effect of 7-0-Methyl-Salsolinol (10 ug/rat) on the Levels of 5-HT
and 5-HIAA in Rat Hypothalamus (A) and Hippocampus (B)
]..lg/g tissue

± s .. e.m.

(N

=

4)

Hippocampus (B)
Time of Sacrifice (hr)

5-HT
-

!.c._

p*

5-HIAA

!_c_

p*

1

0.277 + .045

94 NSD

3

0.344 + .009

117 NSD*

6

0.245 + .006

83 .02*

0. 425 + . 045

142 .01*

12

0.263+.005

89 NSD*

0.428

± .018

143 .01*

24

0.318 + .037

108 NSD

o. 46 6

+ . 04 3

156 .01*

48

0.381 + .022

129 . 01 -

o. 3 8 8

+ . 025

130 . 01

0. 242 + • 017

o. 375

+ . 091

81 NSD
125 NSD

----------------------------------------------------------------------------------------a

%

c =

b NSD

=

% control.

Not significantly different.
1-'
U1
0

Table 14
Summary of Oxidation Potential vs pH of Three
1-Methyl-6,7-Substituted-3,4-Dihydroisoquinolines
Compound

pH

Oxidation Potential E(+) volts

1-Me-6,7-dihydroxy

3.0

+0.64

3,4-dihydroisoquinoline

5.0

+0.49

(l-.r.1e-6, 7-DHIQ)

7.4

+0.33

1-Me-6-hydroxy-7-methoxy

3.0

+0.88

3,4-dihydroisoquinoline

5.0

+0.65

(l-Me-7H-DHIQ)

7.4

+0.50

1-He-6-methoxy-7-hydroxy

3.0

+0.90

3,4-dihydroisoquinoline

5.0

+0.79

(l-Me-6M-DHIQ)

7.4

+0.62

I-'
Ul

I-'

Table 15

± s.e.m.)

Blood Acetaldehyde and Ethanol Concentrations (mg/dl

in Alcoholic Patients on Admission (Day 0) and During Early Detoxification
DAY
1

0

Acetaldehyde (13)

0.350 + .071

0.104 + 0.42

Ethanol ( 13)

229.7 + 29.8

5.0

Number of individual subjects in

N.d.

+ 2.0

2

3

4

<0.04

<0.04

<0.04

N.d.

N.d.

N.d.

parenthes~s.

= Not detectable.

1-'
Ul
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Table 16
Comparison of Regional Brain Levels of DA, 5HT and Acid
Metabolites Obtained in These Studies with Published Values
Compound
DA

DOPAC

Tissue
corpus striatum

corpus striatum

llg/g

±

s.e.m.

Method

Reference

8.45 + 1.04 (a)

HPLC/EDd

9.50 + 0.78 (c)

GC/ED

8.43 + 0.73

Fluoromett'ie

166

7.93 + 0.73

Fluorometric

165

8.78 + 0.89

Fluorometric

201

1.30 + 0.20 (a)

HPLC/ED

1.62 + 0.15 (b)

HPLC/ED

0.79 + 0.45

Fluoromet ric

210

0.90 + 0.21

GC/EC

211

2.25 + 0.37

GC/EC

212

1.95 + 0.13

HPLC/ED

213

--------------------------------------------------------------------------------------~
Ln

uv

Table 16 (Cont'd)
Comparison of Regional Brain Levels of DA, 5HT and Acid
Hetabolites Obtained in These Studies with Published Values
Compound
HVA

5HT

Tissue
corpus striatum

hypothalamus

]lg/g + s.e.m.

Hethod

-

Reference

0.63 + .03 (a)

HPLC/ED

0.85 + .05 (b)

HPLC/ED

0.45 + .01

Fluorometric

210

0.38 + 0.06

Fluorometaic

165

0.69 + 0.06

HPLC/ED

213

0.66 + 0.16

GC/EC

211

0.58 + 0.06

GC/EC

212

0.606 + .034 (a)

HPLC/ED

o. 707

GC/EC

214

0.841 + .059

HPLC/ED

215

0.786 + .049

Fluoromet~ic

201

+ • 050

I-'
lJl

"""

Table 16 (Cont'd)
Comparison of Regional Brain Levels of DA, 5HT and Acid
Metabolites Obtained in These Studies with Published Values
Compound
HIAA

Tissue
hypothalamus

11g/g

± s.e.m.

l'lethod
-

Reference

0.448 + .024 (a)

HPLC/ED

0.323 + .010 (b)

HPLC/ED

0.771 + 0.35

Fluorometric

166

0.514 + .057

HPLC/ED

215

0.400 + .028

HPLC/ED

216

a HPLC/ED combination paired-ion ionic suppression system developed in this dissertation.
b HPLC/ED paired-ion system utilized in this dissertation.
c GC/EC with capillary column developed in this system.
d ED electrochemical detection.
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Figure 1.

CA condensing with a carbonyl to form a Schiff

base intermediate followed by an irreversible intramolecular
cyclization to form a THIQ alkaloid.
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~gure

2.

Condensation products of DA found in the urines

of Parkinsonian patients undergoing L-Dopa treatment.

*

3 , 4 - Dihydroxyphenyl acetaldehyde
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Figure 3.

Suggested pathway for the formation of THPBs

found in the urines of Parkinson's patients undergoing
L-DOPA treatment.
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Figure 4.

-acids

Condensation products of DA and phenylpyruvic

found in the urine of Parkinsonts patients undergoing

L-DOPA treatment.
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Figure 5.

-products

Phenylalanine and phenethylamine (PEA) condensation
found in the urines of PKU individuals and in the

brain and urines of rats made "phenylketonuric".
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166

-

figure 6.

DA/phenylpyruvic acid condensation product found

i n the urines of PKU children and in the brain and urine

of rats with experimentally induced

hyperphenylal~ninemia.
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Figure 7.

Simple THIQs found in the urines and lumbar

spinal fluid of human patients during and after ethanol
intoxication.
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~gure

8.

Representation of liver EtOH oxidation.
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Figure 9.

Possible relationship between EtOH consumption,

a ltered AcA levels, and mitochondrial impairment.
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~gure

10.

Proposed pathway for the biosynthesis of THP

during chronic EtOH ingestion.
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Figure 11.
and AcA.

Formation of simple 1-alkyl-THIQsfrom CAs
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Figure 12.

Examples of naturally occurring plant THIQs.
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figure 13.

Proposed pathWa.y for the biosynthesis of THP

and related THIQs in plants.
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:Figure 14.
of NE.

Possible metabolic routes for the metabolism
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Figure 15.
of DA.

Possible metabolic routes for the metabolism
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!_igure 16.
of 5HT.

Possible metabolic routes for the metabolism
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Figure 17.

Structural similarities between the DA agonists,

apomorphine and bulbocapnine, and the THIQ, THP.
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Figure 18.
from THIQs.

Proposed pathways for the formation of DHIQs
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Figure 19.

Structural similarites between the quinoidamine

tautomer of DHIQs and the oxidized form of 60HDA.
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Figure 20.

Schematic of 60HDA interacting with cellular

nucleophiles.
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Figure 21.

Catechol isoquinolines studied for their

stereoselective a-methylation in vivo.
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Figure 22.

GC results of washing toluene solutions of

gFB-derivatives of NE, DA, SAL, DHBA, 3M-DA, 4M-DA with
ammonium phosphate buffer, pH
B, after treatment.

5.9~

A, before treatment;

A 0.25 mm i.d. x

10M, OV-17, WCOT

glass capillary column with electron-capture detector
was utilized.

GC conditions: Column temperature 130°C,

detector temperature 340°C, injector temperature 250°C,
2
N °2F 0.8 kg/cm , splitter set at 10/1.
2
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Figure 23.

Comparison of (A) capillary vs (B) packed

column GC separations of HFB-derivatives of DHBA, DA,
SAL, 3M-DA, 4M-DA, 6M-SAL and 7M-SAL.

A 0.25 mm i.d.

x 10M, OV-17 WCOT glass capillary column with electroncapture detection was utilized.

Capillary GC conditions:

a

o

Column temperature 130 C, detector temperature 340 C,
2
injector temperature 250°C, N °2F .8kg/cm , splitter
2
setting 10:1.
6

The conventional packed column (1/4 " x

stainless steel, 3% OV-101 on Gas Chrom G-HP, 100/120
0

mesh) conditions: Column temperature 165 C, detector
temperature 340°C, injector temperature 250°C and N °2F
2
25 psi.
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Figure 24.

GC chromatogram of a standard mixture of HFB-

derivatives of DHBA, DA, SAL, 3H-DA, 4M-DA,
7M-SAL.

wcoT

6~-1-SAL

and

Analysis was performed on a 10M x 0.25 mm i.d.

OV-17

detection.

glass capillary column with electron-capture
Chromatographic conditions: Column temperature

130°C, detector temperature 340°C, injector temperature
o

0 F

250 C, N2 2

0.8 kg/em

2

.

and spl1tter set at 10/1.
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Figure 25.

GC chromatogram of a standard mixture of

HFB-derivatives of DHBA, 4,6,7-(0H) THIQ, 6M-4,7-(0H) THIQ
3
2
and 7M-4,6-(0H) THIQ.
2

Analysis was performed on a

10M x 0.25 mm i.d., WCOT, OV-17, glass capillary column
with electron-capture detection.

Chromatographic

conditions: Column temperature 130°C, detector temperature
340°C, injector temperature 250°C, N 02F 0.8 kg/cm
2

splitter set at 10/1.

2

and
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Figure 26.

GC chromatogram of a standard mixture of

PFP/HFIP-derivatives of 1-CSAL, 6M-l-CSAL and 7M-l-CSAL .
.Analysis was performed on a lOH x 0. 25 nun i .d.

1

WCOT 1

OV-17, glass capillary column with electron capture
detection.

Chromatographic conditions: Column temperature

125°C 1 detector temperature 340°C, injector temperature
250

o

c,

0 F

N 2
2

0.8 kg/em

2

and

.

spl~tter

set at 10/1.
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Figure 27.

GC chromatogram of a standard mixture of

pFP/HFIP-derivatives of 3-CSAL, 6M-3-CSAL and 7M-3-CSAL.
Analysis was performed on a 10M x 0.25 mm i.d., WCOT,
ov-17, glass capillary column with electron-capture
detection.
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0

o

c,

Chromatographic conditions: Column temperature
0

detector temperature 340C
0 F

250 C, N2 2

2

0. 8 kg/em,

.

sol~tter

..
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Figure 28.

GC chromatogram of a standard mixture of

HFB-derivatives of 1-He-6,7-DHIQ, l-Me-6M-DHIQ and
l-Me-7r1-DHIQ.

Analysis was performed on a 10r1 x 0. 25 mrn

i.d., WCOT, OV-17, glass capillary column with electroncapture detection.

Chromatographic conditions: Column

temperature 145°C, detector temperature 340°C, injector
temperature 250°C, N °2F 0.8 kg/cm
2
10/1.

2

and splitter setting
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Figure 29.

HPLC chromatogram of a standard mixture of

DOPAC, 5HIAA and HVA.

Analysis was performed on a Bio-Sil

c 18 reverse-phase 25 em column with electrochemical detection.
HPLC conditions: Paired-ion buffer {SmM HSA, 10% MeOH, 1%
HOAc, pH 3.5) with a flow rate of 1.0 ml/min.
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Figure 30.

HPLC chromatogram of a standard mixture of

NE, DHBA, DA, SAL, and 5HT. Analysis was performed on a
18
· s·1
c
· 1
B~o~
reverse p h ase 25 em co 1 umn w1'th e 1 ectroc h em1ca
detection.

HPLC conditions: Paired-ion buffer (8mM HSA,

10% MeOH, 1% ijOAc, pH 3.5) with a flow rate of 1.0 ml/min.
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Figure 31.

HPLC chromatogram of a standard mixture of

NE, DHBA, DOPAC, 5HT, 5HIAA and HVA. Analysis was performed
. s 1'1 C18 reverse p h ase 25 em co 1 umn w1t
. h
on a B1oelectrochemical detection.

HPLC conditions: Ion-

suppression buffer (0.1 NaH P0 /lmM Na 2 EDTA pH 5.0)
2 4
with a flow rate of 1.0 ml/min.
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Figure 32.

HPLC chromatogram of a standard mixture of DA,

DOPAC, SAL, 5HT, 5HIAA, HVA, 7H-SAL and 6M-SAL.
was per f orme d on a

.
B~o-

s ~'1

18

C

Analysis

, reverse p h ase, 25 em

column with electrochemical detection.

HPLC conditions:

Ion-suppression buffer (0 .1 M Na.H Po /lwl Na EDTA, pH 5. 0)
2 4
2
with a flow rate of 1.0 ml/min.
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Figure 33.

HPLC chromatogram of a standard mixture of

4,6,7-(0H) -THIQ, 6M-4,7(0H) THIQ and 7M-4,6(0H) THIQ.
2
2
3
18
.
'1 C , reverse p h ase,
.
Ana 1 ys~s
was per f orme d on a B~o-s~
25 em column with electrochemical detection.

HPLC

conditions: Ion-suppression buffer (0.1 M NaH Po /l roM
2 4
Na EDTA, pH 5.0) with a flow rate of 1.0 ml/min.
2
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Figure 34.

HPLC chromatogram of a standard mixture of

1-CSAL, 6M-l-CSAL and 7M-l~CSAL. Analysis was performed
·
·1 c 18 , reverse p h ase, 25 em co 1 urnn w~t
· h
on a B~o-s~
electrochemical detection.

HPLC conditions: Ion-

suppression buffer (0.1 M NaH Po /l mM Na EDTA, pH 5.0)
2
2 4
with a flow rate of 1.0 ml/min.

223

-1

<2:

V')

u

I

-1

<2:

V')

u

I

I

:::E

1.0

LJ..I
V')

z

0

a..
V')

LJ..I

c::::
c::::

0

1--

u

LJ..I

1--

LJ..I
Cl

'..;::.

t

0

00

I

........

::z
c...

1"'11

.

N

......"'

"'
N

('"")

-l

RETENTION TIME (MIN)

224
Figure 35.

HPLC chromatogram of a standard mixture of

3-CSAL, 6H-3-CSAL and 7M-3-CSAL. Analysis was performed
.
'1 C18 , reverse p h ase, 25 em co 1 umn w1t
. h
on a B1o-S1
electrochemical detection.

HPLC conditions: Ion

suppression buffer (0.1 M NaH 2 Po 4 /lmM Na EDTA pH 5.0)
2
with a flow rate of 1.0 ml/min.
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Figure 36.

HPLC chromatogram of a standard mixture of

1-Me-6,7-DHIQ, l-Me-6M-DHIQ and l-Me-7M-DHIQ.
was performed on a Bio-Sil

c 18 ,

Analysis

reverse phase, 25 em

column with electrochemical detection.

HPLC conditions:

Ion-suppression buffer (0.1 M Na2HP0 /l mM Na EDTA adjusted
2
4
to pH 7.4 with 0.1 M citric acid, 10% MeOH) with a flow
rate of 1.0 ml/min.
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Figure 37.

(A)

Representat~ve

GC chromatogram of a corpus

striatum extracted with 70% aqueous EtOH and isolation on
BioRex-70 from a rat injected ICV with SAL or DA (---).
After Iyophflization. samples were derivatized with HFBA
and analyzed on a 10M x 0.25 i.d., OV-17, WCOT, glass
capillary column with electron-capture detection.

GC

conditions: Column temperature l30°C, detector tenperature
340, injector temperature 250°C, N °2F 0.8 kg/cm
2

2

splitter

set at 10/1.
(B) Representative HPLC chromatogram of a
corpus striatum from a rat injected ICV with SAL.

Tissues

were extracted with 70% aqueous EtOH, isolated on BioRex-70
lyophilized and taken up in 0 .. 1 N H.Cl. P..nalysis 'toTas
.
'1 C18 reverse p h ase, 25 em, co 1 umn
per f orme d on a B1o-S1
with electrochemical detection.

HPLC conditions: Ion-

suppression buffer (0.1 M NaH Po /1
2 4
with a flow rate of 1.0 ml/min.

~1

Na EDTA, pH 5.0)
2
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Figure 38.

(A) Representative GC chromatogram of a corpus

striatum from a rat injected ICV with 4,6,7-(0H) THIQ.
3
Tissues were extracted with 70% aqueous EtOH, isolated on
BioRex-70, lyophilized and derivatized with HFBA.
was performed a 10M x 0.25

~m

i.d.

OV-17

WCOT

Analysis
glass

capillary column with electron-capture detection.

GC

conditions column temperature 130°C, detector temperature
340°C, injector temperature 250, N °2F 0.8 kg/cm
2

2

and splitter

set at 10/1.
(B) Representative HPLC chromatogram of a corpus
striatum from a rat injected ICV with 4,6,7-(0H) THIQ.
3
~issues

were extracted with 70% aqueous EtOH, isolated on

BioRex-70, lyophilized and taken up in O.OlN HCL. Analysis
18
was performed on a Bio-Sil c
reverse phase column with
electrochemical detection.

HPLC conditions: Ion-suppression

buffer (0.1 M NaH Po /l rnt-1 Na EDTA pH 5.0) with a flow rate
2 4
2
of 1. 0 ml/min.

biHll(l~(:H0~):-9~'~17-~W~L~~~~§~=:

biHl
- 2 (HO)-L'17-W9•

---

11.6
9.2
6.8
4.0
INJECT

4.0

6.0

12~05

7.64

8.8

1~-~oo-

'i/~O:§§~~~§~§~~~~~§~

£biH1
(HQ)-L'9'~

3SNOdS3M M01J3130

biHl(HO)-L'9'17.._=========~

'i/9HO -===========::
~01J3130

'"-------------'"\-1- INJECT
3SNOdS3M

231

232
Figure 39.

(A) Representative GC chromatogram of a

hypothalamus from a rat injected ICV with 1-CSAL.

Tissues

were extracted with 70% aqueous EtOH, isolated on BioRex-70
lyophilized and derivatized with PFPA/HFIP.

Analysis was

performed on a 10M x 0.25 mm i.d. OV-17, WCOT, glass
capillary column with electrochemical detection.

GC

conditions: Column temperature 125°C, detector temperature
2
340°C, injector temperature 250°C, N °2F 0.8 kg/crn and
2

splitter set at 10/1.
{B) Representative HPLC chromatogram of a
hypothalamus from a rat injected ICV with 1-CSAL.

Tissues

were extracted with 70% aqueous EtOH, isolated on BioRex-70,
lyophilized and taken up in 0 .rn N' HCl. ·Analysis was
.
'1 C18 , reverse p h ase 25 em co 1 umn w1th
.
per f orme d on a B1o-S1
electrochemical detector.

HPLC conditions: Ion-suppression

buffer (0.1 M N'aH Po /l mM Na EDTA, pH 5.0) with a flow rate
2 4
2
of 1. 0 ml/min.
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Figure 40.

(A) Representative GC chromatogram of

hypothalamus from a rat injected ICV with 3-CSAL.

Tissues

were extracted with 70% aqueous EtOH, isolated on BioRex-70
lyophilized and derivatized with PFPA/HFIP.

Analysis was

performed on a 10M x 0.25 mm i.d., OV-17, 'NCOT, glass
capillary column with electron-capture detection.

GC

conditions: Column temperature 155°C, detector temperature
2
340°C, injector temperature 250°C, N °2F 0.8 kg/cm and
2
splitter set at 10/1.
(B) Representative HPLC chromatogram of a
hypothalamus from a rat injected ICV with 3-CSAL.

Tissues

were extracted with 70% aqueous EtOH, isolated on BioRex-70
lyophilized and brought up in 0.5 ml of O.OlN HCL.
was performed on a Bio-Sil

c 18

reverse phase

column with electrochemical detection.

Analysis

25 em

HPLC conditions:

Ion-suppression buffer (0.1 M NaH Po ;1 mM Na EDTA, pH
2 4
2
5.0) with a flow rate of 1.0 ml/min.
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Figure 41.

Summary of the site-specific in vivo

a-methylation of various catechol-isoquinolines in the
rRt CNS, expressed a percent of total a-methylation.

DOPAMINE

SALSOLINOL
(5)

HO

HO

1-CARBOXY-SALSOLINOL
3-CARBOXY-SALSOLINOL
(60)
~ ../""~ HO..... _L;..~../"~~COOH

NH 2 HO

(95)

CH 3

4,6,7-(0H) 3THIQ
HO
(55)

1-Me-6,7-DHIQ

(QUINOIDAMINE FORM)

· HO

H

HO
(45)

CH 3
NO DETECTABLE 0-METHYLATION

IV

w

~

238

Figure 42.

Levels of 5HT, 5HIAA, HVA and DOPAC (percent

of control) in three rat brain regions 50 min following
ICV administration of catechol isoquinolines (50 ug/animal).
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Figure 43.

Log of the tissue levels of 7M-SAL at different

time points after
hypothalamusi

e

rev

injection ( 5 ug/ventricle )

corpus striatum.
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Figure 44.

Central effects of 7M-SAL on the levels of

biogenic amines and acids.
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Figure 45.

Possible tautomeric forms of DHIQs which

can exist under physiological conditions.
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Figure 46.

W absorption spectra of A, 1-Me-6,7 DHIQ and

B, 1-Me-7M-DHIQ; pH 2-4----; pH 7.0-13----.

247

o::t

A

co

o::t
o::t

("')

N

l

>-

I '

1-

......

I

V')

z

'

I

LJ.J
Cl

....J

I

c:t

u

......

N

0

("')

/

10..

0

N

w

0
0

0
0

<.TI

0
0

0
0

Nr1
o::t

co

o::t
o::t

("')

B

N

A

>-

1......

I'~

V')

I

z

LJ.J
Cl

,

....J

c:t

1-

0

N

0

("')

I

I

u
......
0..

'N

/
N

0
0

w

..j:::o

0
0

0
0

NM

<.TI

0
0

248

Figure 47.

Excitation and emission spectra of A, l-Me-

6,7-DHIQ and B, l-Me-7M-DHIQ.
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Figure 48.

Variation of

1-He-6, 7-DHIQ (0)

fluo~escence

intensity with pH of

and l-~1e-7M-DHIQ (D) ·
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Figure 49.

UV absorption spectra of A, 1-He-6, 7-m·1 DHIQ

and B, 1-He-6M-DHIQ; pH 1-9----; pH 10-13--.
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Figure 50.
DH DHIQ.

Excitation and emission spectra of 1-Me-6,7-
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Figure 51.

Variation of

of 1-Me-6,7-DM DHIQ.

fluoresc~nce

intensity with pH

ex::

LLJ

c:x:
_,J

1-

>
.......

LLJ

:z
.......

1-

LLJ

>I.......
Vi
:z

0

\0

0

257

258
Figure 52.

Cyclic voltanunograrns of 1-He-6, 7-DHIQ; A, pH

3.0 (---); B, pH 5.0 (---); C, pH 7.4
200 rnv/sec sensitivity 211A/crn.
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Figure 53.

Cyclic voltarnmograms of l-Me-7M-DHIQ; A, pH

3.0 (---); B, pH 5.0 (---); C, pH 7.4
200 mv/sec, sensitivity

2uA/cm.
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Figure 54.

Cyclic volta·mmograms of l-Me-6M-DHIQ; A, pH

3.0 (---); B, pH 5.0

(--); C, pH 7.4 (•-•); scan speed

200 rnv/sec, sensitivity

2~A/cm.
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Figure 55.

Representative GC chromatogram of head-space

of control blood spiked with AcA, EtOH and N-propanol
(internal standard) incubated at 37°C, using PoraPak
QS column with flame ionization detection.
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Figure 56.

Comparison of structural similarities between

DHIQs, pyrones, pyridones and tropolones.
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Figure 57.

(A) Proposed alternative binding orientations

of CA substrates at the catechol binding site of COMT,

C-)

meta-binding orientation and para binding orientation (---).
(B) Proposed alternative binding orientations
of catechol-isoquinoline substrates at the catechol-binding
site COHT, para (7) binding orientation (--) and meta (6)
binding orientation (---).
CA binding center; SAM

=

H

= proposed

hydrophobic center; CA=

SN1 binding site.
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Figure 58.

(A) Transition of a 1-Me-6-hydroxy-DHIQ with pH.
{B)

pH.

Transition of 1-Me-6-substituted-DHIQ with
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Figure 59.

(A) Theoretical single peak voltammogram of a

model oxidizable compound.
(B) Theoretical cyclic voltammogram of a model
oxidizable/reducible compound.

2J3

(RED)
A

0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1

0.0
i=O

(OX)

0.42 = Ep
a
B

(RED)

i=O

(OX)
b

274

Figure 60.

Cyclic voltammograms of model compounds show

redox reactions which are; A, fast (reversible); B,
intermediate (guasi-reversible; C, slow (irreversible) .
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Figure 61.

Possible reaction pathways for the electrochemical

oxidation of DHIQs.
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Figure 62.

Possible metabolic routes for 1-CSAL in vivo.
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LIST OF ABBREVIATIONS

AAD

Aromatic acid decarboxylase

AcA

Acetaldehyde

ACN

Acetonitrile

ADH

Alcohol dehydrogenase

ALDH

Aldehyde dehydrogenase

AL203

AluminUP.l oxide

BBB

Blood-brain-barrier

BBr

3

Borontribromide

CA.s

Catecholamines

CNS

Central nervous system

co 2

Carbon dioxide

1-CSAL

1-carboxysalsolinol

3-CSP...L

3-carboxysalsolinol

COMT

Catechol-0-methyl-transferase

DP._

Dopamine

DBH

Doparnine-S-hydroxylase

DDC

L-Dopa decarboxylase

DHBA

Dihydroxybenzylamine

DHIQ

3,4-Dihydroisoquinoline

dH 0
2

Deionized-distilled water

DHPA,cA

3,4-Dihydroxyphenylacetaldehyde

DNLCA

3,4-Deoxynorlaudanosoline carboxylic acid

D 0
2

Deuterium oxide

DOPAC

3,4-Dihydroxyphenylacetic acid

DOPEG

3,4-Dihydroxyphenylethylene glycol

EC

Election capture

EPI

Epinephrine

EtOAc

Ethyl acetate

EtOH

Ethanol

GC

Gas chromatograph

GSH

Glutathione

HBR

Hydrogen bromide

HCHO

Formaldehyde

HFBA

Heptafluorobutyric anhydride

HFIP

Heptafluoroisopropanol

5HIAA

5-Hydroxyindoleacetic acid

HoAc

Acetic acid

HSA

Heptane sulfonic acid

5HT

Serotonin

5HTOL

5-hydroxytryptophol

5HTP

5-hydroxytryphophan

HVA

Homovanillic

I2

Iodine

ICV

Intracerebroventricular

IR

Infra red

acid

Potassium ion
KBr

Potassium bromide

L-DOPA

3,4-Dihydroxyphenylalanine

MAO

Monoamine oxidase
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6M-l-CSAL

6-0-methyl-1-carboxysalsolinol

7M-l-CSAL

7-0-methyl-1-carboxysalsolinol

6M-3-CSAL

6-0-methyl-3-carboxysalsolinol

7M-l-CSAL

7-0-methyl-3-carboxysalsolinol

3M-DA

3-0-methyl-dopamine

4M-DA

4-0-methyl-dopamine

1-Me-6,7-DHIQ

1-methyl-6,7-dihydroxy 3,4-dihydroisoquinoline

1-Me-6,7-DMDHIQ

1-methyl-6,7-dimethoxy 3,4-dihydroisoquinoline

l-Me-6M-DHIQ

1-methyl-6-methoxy-7-hydroxy-3,4-dihydroisoquinoline

l-Me-7M-DHIQ

1-methyl-6-hydroxy-7-methoxy-3,4-dihydroisoquinoline

MeOH

Methanol

MEOS

Microsomal ethanol oxidizing system

MET

Metanephrine

Mg++

Magnesium ion

MOPEG

3-methoxy-4-hydroxyphenylethylene glycol

NMLCA

3-0-methylnorlaudanosolinecorboxylic acid

MS

Mass spectrum

6M-SAL

6-0-methyl-salsolinol

7M-SAL

7-0-methyl-salsolinol

6M-4,7(0H) 2THIQ

6-methoxy-4,7-dihydroxy-tetrahydroisoquinoline

7M-4,6(0H) 2 THIQ

7-methoxy-4,6-dihydroxy-tetrahydroisoquinoline
Nitrogen gas oxygen free
Nitrogen gas extra dry
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Na+

Sodium ion

NAD

Nicotinamide-adenine-dinucleotide oxidized
form

NADH

Nicotinamide-adenine-dinucleotide reduced
form

NE

Norepinephrine

6NH DA
2

6-Amino-dopamine

NLCA

Norlaudanosalinecarboxylic acid

NMR

Nuclear magnetic resonance

NORMET

Normetanephrine

NTs

Neurotransmitters

60HDA

6-Hydroxy-dopamine

OSA

Octane-sulfonic acid

OV-17

Polyphenylmethylsiloxane

OV-101

Polydimethoxysiloxane

PEA

Phenethylamine

PFPA

Pentafluoropropionyl anhydride

PIC

Paired-ion chromatography

PKU

Phenylketonuria

PNMT

Phenethanolarnine-N-methyl-transferase
Phosphorous pentoxide
Reverse phase
Room temperature

SAL

Salsolinol

SAM

S-adenosyl-L-methionine

SCOT

Support coated open tubular

TCA

Citric acid cycle
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TFAA

Trifluoroacetic anhydride

TH

Tyrosine hydroxylase

THBC

Tetrahydro-B-carboline

THIQ

Tetrahydroisoquinoline

4,6,7-(0H) 3 -THIQ
6,7-(0H) 2 -THIQ

4,6,7-Trihydroxy-tetrahydroisoquinoline
6,7-Dihydroxy-tetrahydroisoquinoline

THP

Tetrahydropapaveroline

THPB

Tetrahydroprotoberberine

TLC

Thin layer chromatography

TMQ

Tximetoquinol

VMA

Vanillyrnandelic acid

WCOT

Wall coated open tubular

HPLC

High performance liquid chromatography
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